Document:

EX-10.5

 Exhibit 10.5 

EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 ASSET TRANSFER AND LICENSE AGREEMENT 

This ASSET TRANSFER AND LICENSE AGREEMENT (the “Agreement”) is dated as of April 10, 2015 (the “Effective
Date”) between Alkermes Pharma Ireland Limited, a private limited company incorporated in Ireland (registered number 448848) whose registered address is Connaught House, 1 Burlington Road, Dublin 4, Ireland
(“APIL”), and DV Technology LLC, a Delaware limited liability company whose registered address is c/o Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware 19801, USA (“Purchaser,” and Purchaser
shall include, after the Effective Date, any entity possessing the obligations of Purchaser set forth in this Agreement). 
 RECITALS: 

WHEREAS, APIL desires to sell and assign to Purchaser, and Purchaser desires to purchase and acquire from APIL, part of APIL’s controlled
release drug development business (the “Business”), comprising the Transferred IP and the Transferred Agreements, and a license of the Nanotechnology IP, the OCR IP, the Abuse Resistant Patents and the Licensed Trademarks, subject
to the terms and conditions set forth in this Agreement; and 
 NOW, THEREFORE, in consideration of the respective premises, mutual
covenants and agreements of the parties hereto, and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties hereto agree as follows: 

1. Definitions. 

Abuse Resistant Patents shall mean any patent application owned by APIL as of the Effective Date and listed in Exhibit A-6 hereto (which for purposes of this Agreement shall include certificates of invention and applications for such certificates), together with any patents resulting therefrom, including any
divisionals, continuations, continuations-in-part, substitutions, reissues, re-examinations, revalidations, extensions (including pediatric exclusivity patent extensions), registrations, supplementary protection certificates, renewals, and foreign
equivalents of any such patents or patent applications. 
 Acorda Agreements shall mean (i) Amended and Restated License
Agreement between APIL and Acorda Therapeutics, Inc. dated September 26, 2003, as amended; (ii) Supply Agreement between APIL and Acorda Therapeutics, Inc. dated September 26, 2003, as amended; (iii) Development and Supplemental
Agreement dated January 14, 2011 to Amended and Restated License Agreement dated September 26, 2003 between APIL and Acorda Therapeutics, Inc., as amended, and Supply Agreement dated September 26, 2003 between APIL and Acorda
Therapeutics, Inc., as amended; and (iv) any related ancillary agreements between APIL and Acorda Therapeutics, Inc. or its affiliates. 

Affiliate shall mean, with respect to any Person, any other Person that directly, or through one or more intermediaries,
controls or is controlled by or is under common control with such Person. For purposes of this Agreement, “control” shall mean, as to any Person, the power to direct or cause the direction of the management and policies of such Person,
whether through the ownership of voting securities, by contract or otherwise (and the terms “controlled by” and “under common control with” shall have correlative meanings). For purposes of Section 7 of this
Agreement, APIL shall not be treated as an Affiliate of Purchaser, and Purchaser shall not be treated as an Affiliate of APIL. 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 BiDil Products shall mean BiDil XRTM, a fixed dose combination of
hydralazine hydrochloride and isosorbide dinitrate, and any other pharmaceutical products that may be licensed by APIL pursuant to the NitroMed Agreements. 

Controlled shall mean with respect to any intellectual property, that APIL, in whole or in part, owns or has a license to such
intellectual property and has the ability to grant a license or a sublicense, as applicable, or to otherwise disclose proprietary or trade secret information, to Purchaser or its sublicensees, without paying any consideration to any third party and
without either misappropriating the proprietary or trade secret information of a third party or violating the terms of any agreement or other arrangement with any third party existing and in effect at the time APIL would be required to grant
Purchaser or its sublicensees such license or sublicense. 
 Focalin Agreements shall mean: (i) Preliminary Development
Agreement between APIL and Novartis Pharma AG dated September 21, 2001; (ii) License and Supply Agreement between APIL and Novartis Pharma AG dated December 17, 2004, as amended; and (iii) any related ancillary agreements between
APIL and Novartis Pharma AG or its affiliates. 
 Focalin Products shall mean Focalin XR®, an extended-release oral formulation of dexmethylphenidate, and any other pharmaceutical products that may be licensed by APIL pursuant to the Focalin Agreements. 

Know-How shall mean all proprietary data, information, knowledge, know-how, inventions, discoveries, trade secrets, processes,
techniques, strategies, methods, practices, skills, experience, documents, apparatus, devices, assays, screens, databases (including safety databases), database structures and data analysis methods, compositions, materials, methods, formulas,
improvements, clinical and non-clinical study reports, test data including pharmacological, biological, chemical, biochemical, toxicological, and clinical test data, analytical and quality control data, stability data, studies and procedures. 

Licensed Trademarks shall mean APIL’s trademarks
(i) NanoCrystal®, (ii) SODAS®, (iii) CODAS® and
(iv) BeadTekTM, application and registration details for which, as of the Effective Date, are set out in Exhibit B-2 hereto. 

Meloxicam IV/IM shall mean an aqueous extended-release formulation of the selective COX-2 inhibitor non-steroidal
anti-inflammatory drug meloxicam that has been developed by APIL using NanoCrystal Technology, including an intravenous or intramuscular form existing as of the Effective Date. 

Meloxicam Parenteral Formulation shall mean a parenteral formulation of the selective COX-2 inhibitor non-steroidal
anti-inflammatory drug meloxicam developed at any time on or after the Effective Date by or on behalf of Purchaser using NanoCrystal Technology. For the avoidance of doubt, the Meloxicam Parenteral Formulation shall not be deemed to include
Meloxicam IV/IM. 
 Merck Agreement shall mean the Technology Transfer and License Agreement between APIL and Merck &
Co, Inc. dated July 26, 1999, as amended. 

  
 2 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 NanoCrystal Technology shall mean APIL’s proprietary technology
comprising: 
 a. nanoparticulate dispersions of compounds stabilized against particle growth or agglomeration, and materials, methods and
equipment used for making such dispersions; and 
 b. formulations, including finished formulations incorporating or derived from such
dispersions, and materials, methods and equipment used for making such dispersions, provided such formulations, materials, methods and equipment are for the maintenance and control of (i) nanoparticulate size of the nanoparticulate component;
(ii) redispersability of the nanoparticle nanoparticulate component in biological fluids; (iii) the rate of release or delivery of the nanoparticle nanoparticulate component in vivo; or (iv) the anatomical site of release of the
nanoparticle nanoparticulate component from the finished dosage form of a pharmaceutical product. 
 Nanotechnology IP shall
mean the Nanotechnology Know-How and the Nanotechnology Patents. 
 Nanotechnology Know-How shall mean any Know-How Controlled
by APIL as of the Effective Date relating to Meloxicam IV/IM. 
 Nanotechnology Patents shall mean all patents and patent
applications owned by APIL as of the Effective Date and listed in Exhibit A-2 hereto (which for purposes of this Agreement shall include certificates of invention and applications for such certificates), together with any patents resulting
therefrom, including any divisionals, continuations, continuations-in-part, substitutions, reissues, re-examinations, revalidations, extensions (including pediatric exclusivity patent extensions), registrations, supplementary protection
certificates, renewals, and foreign equivalents of any such patents or patent applications. 
 NitroMed Agreements shall mean
(i) License Agreement between APIL and NitroMed, Inc. dated February 9, 2007; and (ii) any related ancillary agreements between APIL and NitroMed, Inc. or its affiliates. 

OCR IP shall mean the OCR Know-How and the OCR Patents. 

OCR Know-How shall mean any Know-How Controlled by APIL as of the Effective Date relating to OCR Technology. 

OCR Patents shall mean all patents and patent applications owned by APIL as of the Effective Date and listed in Exhibit A-3 hereto, (which for purposes of this Agreement shall include certificates of invention and applications for such certificates), together with any patents resulting therefrom, including any
divisionals, continuations, continuations-in-part, substitutions, reissues, re-examinations, revalidations, extensions (including pediatric exclusivity patent extensions), registrations, supplementary protection certificates, renewals, and foreign
equivalents of any such patents or patent applications. 
 OCR Technology shall mean (i) APIL’s proprietary oral
controlled release SODAS® (Spheroidal Oral Drug Absorption System) technology comprising a multiparticulate drug delivery system based on the production of controlled-release beads typically
of approximately 1 to 2 mm in diameter containing drug plus excipients coated with product-specific modified-release polymers to achieve varying degrees of modified release depending upon the required release profile for any particular product;
control of drug release may be a result of the use of pH-dependent or independent coatings and a single polymer system or a combination of polymers. Once produced, the coated beads are formulated into the final dosage form;

  
 3 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
and (ii) APIL’s formulation technology based on the production of a population of coated beads containing a gelling agent plus excipients. These gelling agent-containing beads are
designed for abuse deterrent formulations and do not contain any drug. OCR Technology excludes APIL Know-How relating to alcohol dose dumping. 

Paladin Agreements shall mean (i) License and Distribution Agreement between APIL and Paladin Labs Inc. dated May 12,
2011; and (ii) any related ancillary agreements between APIL and Paladin Labs Inc. or its affiliates. 
 Paladin Patents
shall mean all patents and patent applications licensed by APIL to Paladin as of the Effective Date pursuant to the Paladin Agreements, including those listed in Exhibit A-5 hereto. 

Paladin Products shall mean any pharmaceutical products that may be licensed by APIL pursuant to the Paladin Agreements. 

Person shall mean a person, corporation, partnership, limited liability company, joint venture, trust or other entity or
organization. 
 Ritalin Agreements shall mean (i) Development, License and Supply Agreement between APIL and Novartis
Pharmaceuticals Corporation dated December 17, 1997, as amended; and (ii) any related ancillary agreements between APIL and Novartis Pharmaceuticals Corporation or its affiliates. 

Ritalin Products shall mean Ritalin SR®, a sustained-release oral
formulation of methylphenidate, and any other pharmaceutical products that may be licensed by APIL pursuant to the Ritalin Agreements. 

Transferred Agreements shall mean: (i) the Focalin Agreements; (ii) the Ritalin Agreements; (iii) the Paladin
Agreements; (iv) the Verapamil Agreements; (v) the Zogenix Agreements; (vi) the NitroMed Agreements; and (vii) the Transferred License and Settlement Agreements. 

Transferred IP shall mean (i) the Transferred Patents and (ii) the Transferred Trademarks, in each case, together
with: (a) the right to claim priority under the Paris Convention and any other similar provision of national or international law, (b) the right to sue and recover damages or other compensation or equitable relief for past, present or
future infringement, misappropriation or violation thereof, and (c) the right to fully and entirely stand in the place of APIL in all matters related thereto. 

Transferred License and Settlement Agreements shall mean those License Agreements and Settlement Agreements as listed in
Exhibit C hereto. 
 Transferred Patents shall mean (i) the Paladin Patents, (ii) the Zogenix Patents; and
(iii) all patents and patent applications owned by APIL as of the Effective Date and listed in Exhibit A-1 hereto (the patents and patent applications listed in subsections A-1.5, A-1.6 and A-1.7
of Exhibit A-1 being described as the “Grant-Back Patents”) (which for purposes of this Agreement shall include for the patents and patent applications described in each of clauses (i), (ii), and (iii), the certificates of
invention and applications for such certificates), together with (for the patents and patent applications described in each of clauses (i), (ii) and (iii)) any patents resulting therefrom, including any divisionals, continuations,
continuations-in-part, substitutions, reissues, re-examinations, revalidations, extensions (including pediatric exclusivity patent extensions), registrations, supplementary protection certificates, renewals, and foreign equivalents of any such
patents or patent applications. 

  
 4 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Transferred Trademarks shall mean the Verelan trademark owned by APIL used with
respect to Verapamil Products as of the Effective Date, related registrations as listed in Exhibit B-1 hereto, and the goodwill associated therewith. 

Verapamil Agreements shall mean (i) License and Supply Agreement between APIL and Kremers Urban Pharmaceuticals, Inc. dated
January 1, 2014; (ii) Amended and Restated License and Supply Agreement between APIL and Watson Laboratories, Inc. dated June 26, 2003, as amended; and (iii) any related ancillary agreements between APIL and either Kremers Urban
Pharmaceuticals, Inc. or its affiliates or Watson Laboratories, Inc. or its affiliates. 
 Verapamil Products shall mean any
sustained-release oral formulations of verapamil hydrochloride and any other pharmaceutical products that may be licensed by APIL pursuant to the Verapamil Agreements. 

Zanaflex Agreements shall mean (i) Asset Purchase Agreement between APIL and Acorda Therapeutics, Inc. dated July 21,
2004; (ii) Supply Agreement between APIL and Acorda Therapeutics, Inc. dated July 21, 2004; and (iii) any related ancillary agreements between APIL and Zogenix, Inc. or its affiliates. 

Zogenix Agreements shall mean: (i) License Agreement between APIL and Zogenix, Inc. dated November 27, 2007, as
amended; (ii) Development and Clinical Supply Agreement between APIL and Zogenix, Inc. dated December 20, 2007; (iii) Commercial Manufacturing and Supply Agreement between APIL and Zogenix, Inc. dated November 2, 2012; and
(iv) Second Generation (ZX004) Commercial Manufacturing and Supply Agreement between Daravita Limited and Zogenix, Inc. dated March 5, 2015 (v) any related ancillary agreements between APIL and Zogenix, Inc. or its affiliates.

 Zogenix Patents shall mean all patents and patent applications licensed by APIL to Zogenix as of the Effective Date
pursuant to the Zogenix Agreements, including those listed in Exhibit A-4 hereto. 
 Zogenix Products shall mean
ZohydroTM ER, an extended-release oral formulation of hydrocodone bitartrate, and any other pharmaceutical products that may be licensed by APIL pursuant to the Zogenix Agreements. 

2. Transfer of Transferred IP.  

a. Transferred IP. Subject to the terms and conditions of this Agreement, effective the Effective Date, APIL hereby sells, assigns,
transfers, conveys and delivers to Purchaser, and Purchaser hereby purchases, acquires and accepts from APIL, all of APIL’s right, title and interest on the Effective Date throughout the world in and to the Transferred IP. 

b. Licenses Back of Paladin Patents and Zogenix Patents. Subject to the terms and conditions of this Agreement, effective the
Effective Date, Purchaser hereby grants APIL a non-exclusive, worldwide license under the Grant-Back Patents, the Paladin Patents and the Zogenix Patents, with the right to sublicense, to develop, make, have made, use, sell, offer to sell and import
pharmaceutical products for the treatment of any human disease, disorder or condition, subject to the Paladin Agreements, the Zogenix Agreements, the Focalin Agreements and the Ritalin Agreements. Subject to the terms and conditions of this
Agreement, Purchaser hereby also grants APIL an exclusive, worldwide license under the Grant-Back Patents, the Paladin Patents and the Zogenix Patents, with the right to sublicense, to develop, make, have made, use, sell, offer to sell and import
any pharmaceutical products licensed, supplied or developed under 

  
 5 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
the Acorda Agreements. Notwithstanding anything to the contrary contained in this Agreement, the parties hereby agree that all of the licenses granted by Purchaser to APIL under this
Section 2(b) shall extend until the expiration or invalidation of all Grant-Back Patents, Paladin Patents and Zogenix Patents. 

c. Transfer of Transferred Patents. After the Effective Date, APIL shall execute, or procure the execution of, such formal documents
of sale and/or assignment as are required consistent with the terms and conditions of this Agreement to formally record the change of title to the Transferred Patents to Purchaser in a timely manner. 

d. Transfer of Transferred Trademarks. After the Effective Date, APIL shall execute, or procure the execution of, such formal
documents of sale and/or assignment as are required consistent with the terms and conditions of this Agreement to formally record the change of title to the Transferred Trademarks to Purchaser in a timely manner. 

e. Prosecution and Enforcement. Purchaser shall have the right to file, prosecute (including any oppositions, appeals, prosecution
before the U.S. Patent Office and Patent Trial and Appeal Board, as well as post-grant procedures such as, for example, interference proceedings, Inter Partes Review, Post Grant Review, re-examination, reissue, and derivation procedures) and
maintain (“Prosecute”) and defend and enforce (“Enforce,” and collectively, “Prosecute and Enforce”) the Transferred Patents at its sole discretion and cost and expense. Purchaser shall keep APIL
reasonably informed of activities undertaken to Prosecute and Enforce the Transferred Patents and provide APIL with copies of material correspondence and filings relating to activities undertaken to Prosecute and Enforce the Transferred Patents.

 3. License. 
 a.
Nanotechnology License. Subject to the terms and conditions of this Agreement, effective the Effective Date, APIL hereby grants Purchaser an exclusive, worldwide license under the Nanotechnology IP, with the right to sublicense, to develop,
make, have made, use, sell, offer to sell and import Meloxicam IV/IM and Meloxicam Parenteral Formulation for the treatment of any human disease, disorder or condition, subject to the Merck Agreement. Notwithstanding anything to the contrary
contained in this Agreement, the parties hereby agree that all of the licenses and rights granted by APIL to Purchaser under this Section 3(a) shall be perpetual, unless terminated pursuant to the provisions of Exhibit D hereto.

 b. OCR Licenses. Subject to the terms and conditions of this Agreement, the Acorda Agreements and the Zanaflex Agreements,
effective the Effective Date, APIL hereby grants Purchaser a non-exclusive, worldwide license under the OCR IP, with the right to sublicense, to develop, make, have made, use, sell, offer to sell and import pharmaceutical products for the treatment
of any human disease, disorder or condition. Subject to the terms and conditions of this Agreement, effective the Effective Date, APIL hereby also grants Purchaser an exclusive, worldwide license under the OCR IP, with the right to sublicense, to
develop, make, have made, use, sell, offer to sell and import the BiDil Products, the Focalin Products, the Ritalin Products, the Paladin Products, the Verapamil Products and the Zogenix Products. Notwithstanding anything to the contrary contained
in this Agreement, the parties hereby agree that all of the licenses and rights granted by APIL to Purchaser under this Section 3(b) shall be perpetual, unless terminated pursuant to the provisions of Exhibit D hereto. 

c. Abuse Resistant Patents License. Subject to the terms and conditions of this Agreement, effective the Effective Date, APIL hereby
grants Purchaser an exclusive, worldwide license under the 

  
 6 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Abuse Resistant Patents, with the right to sublicense, to develop, make, have made, use, sell, offer to sell
and import the Paladin Products and the Zogenix Products. Notwithstanding anything to the contrary contained in this Agreement, the parties hereby agree that all of the licenses granted by APIL to Purchaser under this Section 3(c) shall
extend until the expiration or invalidation of all Abuse Resistant Patents. 
 d. Delivery of Licensed Know-How. Promptly following
the Effective Date, APIL shall make available to Purchaser the Nanotechnology Know-How and the OCR Know-How in an orderly fashion and in a manner such that the value of such Know-How is preserved in all material respects. 

e. Trademark License. Subject to the terms and conditions of this Agreement, effective the Effective Date, APIL hereby grants
Purchaser a non-exclusive, worldwide license to use the Licensed Trademarks for the advertising, promotion, marketing, distribution and sale of pharmaceutical products covered by the licenses granted in Sections 3(a), (b) and
(c) hereof. Purchaser shall have the right to grant sublicenses under the foregoing non-exclusive license to its sublicensees under Sections 3(a), (b) and (c) hereof, subject to the provisions of this
Section 3(e). Purchaser hereby acknowledges APIL’s exclusive right, title and interest in and to the Licensed Trademarks and agrees that Purchaser and its sublicensees will not at any time do, or cause to be done, any act or thing
contesting or in any way intending to impair the validity of and/or APIL’s exclusive right, title and interest in and to the Licensed Trademarks. Purchaser and its sublicensees will not in any manner represent that they own the Licensed
Trademarks, and Purchaser hereby acknowledges that use of the Licensed Trademarks as set forth in this Section 3(e) shall not create any rights, title or interest in or to the Licensed Trademarks in favor of Purchaser or its
sublicensees, but that all use of the Licensed Trademarks by Purchaser and its sublicensees shall inure to the benefit of APIL. Purchaser shall submit to APIL for its review and approval samples of any proposed use of the Licensed Trademarks at
least fifteen (15) days prior to such use by Purchaser. APIL shall review any proposed use of the Licensed Trademarks within fifteen (15) days of Purchaser’s written request, and if APIL does not either approve or decline to approve
such use within such 15-day period, such use shall be automatically deemed approved. Any such approval shall be deemed to be approval of the same or similar uses of the Licensed Trademarks thereafter. APIL shall not unreasonably withhold, delay or
condition any such approval request by Purchaser. 
 f. Prosecution. APIL shall have the right to Prosecute any issued patent or
pending patent application within the Nanotechnology Patents, the OCR Patents, and the Abuse Resistant Patents at its sole discretion and cost and expense. APIL shall keep Purchaser reasonably informed of all activities during the course of such
prosecution and provide Purchaser with copies of material correspondence and filings relating to such activities. At APIL’s request and expense, Purchaser will cooperate to Prosecute the Nanotechnology Patents, the OCR Patents and the Abuse
Resistant Patents. Without prejudice to the generality of the foregoing sentence, Purchaser shall keep APIL reasonably informed from time-to-time of activities relating to Zogenix Products that are encompassed by the Abuse Resistant Patents and
shall reasonably allow APIL to use data and information generated by Purchaser relating to such Zogenix Products to Prosecute the Abuse Resistant Patents. 

If in addition to APIL’s activities to Prosecute the Abuse Resistant Patents and the Nanotechnology Patents, Purchaser wishes with respect to any Abuse
Resistant Patent or any Nanotechnology Patent listed in subsection A-2.6 of Exhibit A-1 to have a divisional, continuation or continuation-in-part application filed that solely claims a compound, composition, method of making or method of
using compounds or compositions within the scope of Purchaser’s exclusive license hereunder, then Purchaser shall notify APIL and, subject to APIL’s approval, which shall not unreasonably withheld, delayed or conditioned, APIL will use
commercially reasonable efforts to Prosecute such patent application, at Purchaser’s cost 

  
 7 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
and expense. Promptly upon receipt, APIL will provide Purchaser with all patent office documents relating to such prosecution, and will also provide drafts of responses to office actions and
other substantive filings with any patent office regarding such patent application sufficiently in advance of their submission to enable review and comment by Purchaser. APIL will consider in good faith all comments timely made by Purchaser. 

g. Enforcement. APIL shall have the first right to Enforce any issued patent within the Nanotechnology Patents, the OCR Patents, or
the Abuse Resistant Patents. To the extent necessary, Purchaser will cooperate with APIL, at APIL’s cost and expense, to carry out such enforcement, including joining as a party. All costs and expenses of such enforcement action will be borne
by APIL, and APIL shall retain any recovery from such an enforcement action. Notwithstanding the foregoing, Purchaser may voluntarily join such enforcement action if the action pertains to an Infringing Activity (as defined below), subject to
APIL’s right to control such action. Where Purchaser so joins such an enforcement action, Purchaser and APIL will share all costs and expenses thereof equally and will also share any recovery from such action equally. APIL shall not enter into
any settlement agreement that would materially harm Purchaser’s rights pursuant to this Agreement without Purchaser’s prior written consent, which shall not be unreasonably withheld, delayed or conditioned. Both APIL and Purchaser shall
promptly notify the other party, as applicable, of any infringing activity of which they are aware with respect to any of the Nanotechnology Patents, OCR Patents, and/or Abuse Resistant Patents within the scope of an exclusive license granted to
Purchaser pursuant to this Agreement to the Meloxicam Parenteral Formulation, Meloxicam IV/IM, the BiDil Products, the Focalin Products, the Ritalin Products, the Paladin Products, the Verapamil Products or the Zogenix Products (an
“Infringing Activity”). 
 To the extent that APIL declines to Enforce any such issued patent within the Nanotechnology Patents, the OCR
Patents, or the Abuse Resistant Patents with respect to an Infringing Activity, Purchaser shall have the option to Enforce such patent, at its own cost and expense, provided that Purchaser can demonstrate to APIL’s reasonable satisfaction that
(i) Purchaser is contractually obligated under a Transferred Agreement to Enforce, or to allow the counterparty to such Transferred Agreement to Enforce, such patent with respect to such Infringing Activity or (ii) (A) permitting the
Infringing Activity would have a materially adverse effect on Purchaser’s and its sublicensees’ sales of the product exclusively licensed under such patent, and (B) based on a due care determination, including obtaining competent
legal advice, the Infringing Activity exists. In such cases, Purchaser will have sole control of such enforcement at its cost and expense. To the extent necessary, APIL will cooperate with Purchaser, at Purchaser’s cost and expense, to carry
out such enforcement, including joining as a party. APIL shall also have the right, at its option and its cost and expense, to join in any such enforcement action taken by Purchaser, subject to Purchaser’s right to control such action. Any
recovery from an enforcement action involving a patent within the Abuse Resistant Patents shall belong solely to Purchaser. For any recovery from an enforcement action involving a patent within the Nanotechnology Patents or OCR Patents, APIL shall
be entitled to fifty percent (50%) of such recovery, provided however, that fifty percent (50%) of the legal fees, costs and expenses of such enforcement action incurred by Purchaser shall be deducted from APIL’s portion of the
recovery. Purchaser shall not enter into any settlement agreement regarding the Nanotechnology Patents, OCR Patents, or Abuse Resistant Patents without APIL’s prior written consent which shall not be unreasonably withheld, delayed or
conditioned. 
 The Parties agree that with respect to Purchaser’s obligations to Zogenix, Inc. under the Zogenix Agreements the Abuse Resistant
Patents shall be deemed to be “Elan Patents” (pursuant to clause (d) of the definition of Elan Patents under the License Agreement between APIL and Zogenix, Inc. dated November 27, 2007, as amended). 

  
 8 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 4. Transferred Agreements. Subject to the terms and conditions of this Agreement,
effective the Effective Date, APIL hereby assigns to Purchaser APIL’s rights, and Purchaser hereby assumes APIL’s obligations, under the Transferred Agreements, if such Transferred Agreements are assignable at such time, except to the
extent such rights and obligations relate to performance or non-performance under the Transferred Agreements on or prior to the Effective Date. On the Effective Date and thereafter from time to time until all Transferred Agreements are assigned,
APIL shall transfer to Purchaser copies of the Transferred Agreements and such information in APIL’s possession as is reasonably necessary to continue conducting business under such Transferred Agreements. If any Transferred Agreement is not
assignable as of the Effective Date, APIL shall use commercially reasonable efforts to seek the consent of the applicable third party(ies) to assign such Transferred Agreement to Purchaser and, if and when such consent(s) are obtained, Purchaser
shall be assigned APIL’s rights and shall assume APIL’s obligations under such Transferred Agreement, except to the extent such rights and obligations relate to performance or non-performance under the Transferred Agreement on or prior to
the Effective Date. To the extent permitted by applicable law and by the terms of the applicable Transferred Agreement, any Transferred Agreement that is not assignable to Purchaser as of the Effective Date shall be held, as of and from the
Effective Date, by APIL for the benefit and burden of Purchaser and the covenants and obligations thereunder shall be fully performed by Purchaser on APIL’s behalf and all rights, liabilities and obligations existing thereunder, as of and from
the Effective Date, shall be for Purchaser’s account. To the extent permitted by applicable law and by the terms of the applicable Transferred Agreement, APIL shall take or cause to be taken, at Purchaser’s expense, such actions as
Purchaser may reasonably request which are required to be taken in order to provide Purchaser with the benefits and burdens of the Transferred Agreements that are not assignable as of the Effective Date. From and after the Effective Date, without
Purchaser’s prior consent, and subject to Purchaser’s compliance with APIL’s obligations under the applicable Transferred Agreement that are not assignable as of the Effective Date, APIL shall not take, permit to be taken or omit to
take any action, in each case, within APIL’s reasonable control, which would give the counterparty to such Transferred Agreement the right to terminate such Transferred Agreement or which would alter any of APIL’s rights or obligations
under such Transferred Agreement in a manner that would materially adversely affect Purchaser’s rights and benefits under this Agreement. In the event Purchaser fails to substantially comply with APIL’s obligations under a Transferred
Agreement that is not assignable as of the Effective Date or the counterparty to such Transferred Agreement gives notice of a breach or default under such Transferred Agreement in connection with Purchaser’s failure to comply with APIL’s
obligations under such Transferred Agreement, then APIL shall have the right to take action to terminate such Agreement. APIL shall promptly pay over to Purchaser the amount of all payments received by it in respect of all such Transferred
Agreements not assigned as of the Effective Date, to the extent such payments relate to performance after the Effective Date, net of any costs and expenses of APIL related to providing Purchaser with the benefits and burdens of such Transferred
Agreements and net of any taxes incurred by APIL related to the provision of such benefits and burdens to Purchaser and the receipt of payments under such Transferred Agreements. 

5. Consideration. In consideration of APIL’s transfer of the Transferred IP and Transferred Agreements to Purchaser in accordance
with Sections 2 and 4 hereof and the grant by APIL of the licenses to Purchaser in accordance with Section 3 hereof, Purchaser shall upon execution of this Agreement pay to APIL (a) [* * *] US Dollars (US$[* * *]) in
cash plus (b) the Earn-Out Consideration as described in Exhibit D hereto. The cash consideration allocable to any Irish patents forming part of the Transferred IP will amount to €[* * *]. All consideration will be paid subject to
any withholding or deduction required by law. No portion of the Earn-Out Consideration as described in Exhibit D hereto will be paid in respect of the user of an Irish patent. To the extent that any of the Transferred Agreements constitute
Irish situated property which is not exempt from stamp duty under section 101 of the Stamp Duties Consolidation Act, 1999, no consideration is allocated to such Transferred Agreement. 

  
 9 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 6. Warranties. APIL hereby represents and warrants to Purchaser as of the Effective
Date as follows: 
 (a) Corporate Existence and Power. APIL is a corporation duly organized and validly existing under the
laws of Ireland, and has all requisite power and authority to own and operate its properties and to carry on its business as now conducted. 

(b) Authority and Binding Agreement. APIL has the corporate power and authority to enter into this Agreement and perform its
obligations hereunder. APIL has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder. The Agreement has been duly executed and delivered
by APIL and constitutes a legal, valid and binding obligation of APIL that is enforceable against it in accordance with its terms; except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium
and other laws relating to or affecting creditors’ rights generally and by general equitable principles and public policy constraints (including those pertaining to limitations and/or exclusions of liability, competition law, penalties and
jurisdictional issues including conflicts of law). 
 (c) No Conflict. The execution, delivery and performance of this
Agreement by APIL does not conflict with, and would not result in a breach or violation of or constitute a default under (i) any material agreement, instrument or understanding, oral or written, to which it is a party or by which it may be
bound; (ii) the provisions of its charter or operative documents or bylaws; or (iii) any material applicable law, or any judgment, decree or order of any court, governmental body or administrative or other agency having jurisdiction over
it. 
 7. Non-Compete. During the period beginning on the Effective Date and ending [* * *] (the “Non-Compete
Period”), except for ownership of the equity in Recro Pharma, Inc. issued pursuant to the warrant described in the Purchase and Sale Agreement dated March 7, 2015 by and among, APIL, Daravita Limited, Eagle Holdings USA, Inc., Recro
Pharma LLC, and Recro Pharma, Inc. (the “Purchase Agreement”), APIL and its Affiliates agree not to directly or indirectly engage in, or have an ownership interest in, any business or enterprise (or subsidiary or division thereof)
that engages in the development, license, manufacture, testing, packaging, storage, sale and shipment of Meloxicam IV/IM or Meloxicam Parenteral Formulation, or the underlying molecules or salts thereof in combination with the Nanotechnology IP
covering such products (a “Competing Business”). If APIL and/or its Affiliates are directly or indirectly acquired by (whether by merger, acquisition of assets or equity, or otherwise), or directly or indirectly acquire (whether by
merger, acquisition of assets or equity, or otherwise), a third party which engages in a Competing Business, such third party and its Affiliates (other than APIL and/or its Affiliates existing prior to the date of such acquisition) shall not be
restricted from continuing to engage in such Competing Business pursuant to this Section 7, provided that the rights of such third party and its Affiliates to utilize the Nanotechnology IP in such Competing Business existed prior
to the date of such acquisition. 
 (b) Each party acknowledges and agrees that the provisions of this Section 7
are reasonable and necessary to protect the legitimate business interests of the other party, including without limitation such party’s confidential information and goodwill. Each party agrees, and shall not contest, that the other party’s
remedies at law for any breach or threat of breach by such party or its Affiliates of the provisions of this Section 7 will be inadequate, and that the other party shall be entitled to an injunction or injunctions to prevent breaches of
the provisions of this Section 7  

  
 10 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
and to enforce specifically such terms and provisions, in addition to any other remedy to which the other party may be entitled at law or in equity. The restrictive covenants contained in this
Section 7 are covenants independent of any other provision of this Agreement or other agreement between the parties and the existence of any claim which a party may allege against another party under any provision of this Agreement, any
other agreement, or otherwise will not prevent the enforcement of the covenants in this Section 7. If any of the provisions contained in this Section 7 shall for any reason be held to be excessively broad as to duration,
scope, activity or subject, then such provision shall be construed by limited and reducing it, so as to be valid and enforceable to the extent compatible with applicable law or the determination by a court of competent jurisdiction. The parties
agree and intend that a party’s obligations under this Section 7 will be tolled during any period that such party is found to be in breach of any of the obligations under this Section 7, so that the other party is
provided with the full benefit of the restrictive periods set forth herein. 
 8. Disclaimer. EXCEPT FOR THE REPRESENTATIONS AND
WARRANTIES IN SECTION 6 OF THIS AGREEMENT, NO PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES IN THIS AGREEMENT, EXPRESS OR IMPLIED, REGARDING THE SUBJECT MATTER OF THIS AGREEMENT. WITHOUT LIMITING THE FOREGOING, EXCEPT FOR THE REPRESENTATIONS
AND WARRANTIES IN SECTION 6 OF THIS AGREEMENT, APIL MAKES NO REPRESENTATION, GUARANTY OR WARRANTY IN THIS AGREEMENT REGARDING THE TRANSFERRED IP, TRANSFERRED AGREEMENTS, NANOTECHNOLOGY IP, OCR IP, ABUSE RESISTANT PATENTS AND LICENSED
TRADEMARKS, INCLUDING, WITHOUT LIMITATION, AS TO THE CONDITION OF TITLE, ENFORCEABILITY, SUITABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, MERCHANTABILITY, VALIDITY, REGISTRABILITY, NON-INFRINGEMENT OR ANY OTHER WARRANTY, WHETHER EXPRESS OR IMPLIED
OR BY OPERATION OF LAW. 
 9. Further Assurances. APIL shall use reasonable efforts to take actions and execute and deliver documents
that Purchaser may reasonably request to effect the terms of this Agreement, to perfect Purchaser’s title in and to the Transferred IP and to assign the Transferred Agreements. 

10. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without
giving effect to any principles, statutory provisions or other rules of choice of law that would require the application of the laws of a different state or country. 

11. Entire Agreement; Modification. This Agreement sets forth the entire agreement and understanding between the parties as to the
subject matter hereof and thereof and supersedes all prior and contemporaneous negotiations, agreements, representations, understandings and commitments between the parties with respect thereto. There shall be no amendments or modifications to this
Agreement, except by a written document referencing this Agreement which is signed by both parties. 
 12. Counterparts. This
Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement. 
 [SIGNATURE PAGE
FOLLOWS] 

  
 11 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 IN WITNESS WHEREOF, each of the parties hereto has caused its duly authorized representative
to execute this Agreement as of the date first set forth above. 
  

			
	ALKERMES PHARMA IRELAND LIMITED
		
	By		 /s/

	Name:		
	Title:		
	
	DV TECHNOLOGY LLC
		
	By		 /s/

	Name:		
	Title:		

  
 12 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit A-1 

Transferred Patents 
 A-1.1 “Reduction of
Intravenously Administered Nanoparticulate-Formulation-Induced Adverse Physiological Reactions” 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent /

Publication No.
	 	 Normal Expiry

Date

								
	01.0056.US	 	ORD	 	United States	 	08/696,754	 	14 Aug 1996	 	Granted	 	5,834,025	 	14 Aug 2016
	01.0056.US	 	REI	 	United States	 	12/027,100	 	06-Feb-2008	 	Granted	 	RE41,884 E	 	14-Aug-2016
	03.0056.CA	 	PCT	 	Canada	 	2232879	 	25-Sep-1996	 	Granted	 	2232879	 	25-Sep-2016
	03.0056.EP	 	DIV *	 	European Patent Convention	 	2010181619.7	 	29-Sep-2010	 	Pending	 	2 275 094 A	 	25-Sep-2016

  

	*	Divisional from EP 96932321.1 (EP 0 859 604) 

 A-1.2 “Nanoparticulate Compositions Having Lysozyme as a
Surface Stabilizer” 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent No.
	 	 Normal Expiry

Date

								
	01.0083.US	 	ORD	 	United States	 	10/357,514	 	04-Feb-2003	 	Granted	 	7459283	 	10-Jul-2026
	01.0083.US	 	CON	 	United States	 	12/292,091	 	12-Nov-2008	 	Granted	 	8323641	 	04-Feb-2023
	01.0083.US	 	CON	 	United States	 	13/693,858	 	04-Dec-2012	 	Granted	 	8652464	 	12-Nov-2028
		 	CON	 	United States	 	14/182,097	 	17-Feb-2014	 	Pending	 		 	
	03.0083.AT	 	PCT	 	Austria	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.BE	 	PCT	 	Belgium	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.BG	 	PCT	 	Bulgaria	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.CA	 	PCT	 	Canada	 	2475092	 	04-Feb-2003	 	Granted	 	2475092	 	04-Feb-2023
	03.0083.CZ	 	PCT	 	Czech Republic	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.DK	 	PCT	 	Denmark	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent No.
	 	 Normal Expiry

Date

	03.0083.EP	 	EPC	 	European Patent Convention	 	03737537.5	 	04-Feb-2003	 	Granted	 	1 471 887	 	
	03.0083.FI	 	PCT	 	Finland	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.FR	 	PCT	 	France	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.DE	 	PCT	 	Germany	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.GR	 	PCT	 	Greece	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.HU	 	PCT	 	Hungary	 	EP Validation	 	04-Feb-2003	 	Granted	 	E008527	 	04-Feb-2023
	03.0083.IE	 	PCT	 	Ireland	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.IT	 	PCT	 	Italy	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.JP	 	PCT	 	Japan	 	2003-565446	 	04-Feb-2003	 	Granted	 	4598399	 	04-Feb-2023
	03.0083.NL	 	PCT	 	Netherlands	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.PT	 	PCT	 	Portugal	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.SK	 	PCT	 	Slovakia	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.ES	 	PCT	 	Spain	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.SE	 	PCT	 	Sweden	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.CH/LI	 	PCT	 	Switzerland / Liechtenstein	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023
	03.0083.GB	 	PCT	 	United Kingdom	 	EP Validation	 	04-Feb-2003	 	Granted	 	1 471 887	 	04-Feb-2023

 A-1.3 “Nanoparticulate Meloxicam Formulations” 

 

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent /

Publication No.
	 	 Normal Expiry

Date

								
	01.0099.US	 	ORD	 	US	 	10/784,900	 	24-Feb-2004	 	Granted	 	8512727	 	25-Dec-2022
	01.0099.US	 	CON	 	US	 	13/941,076	 	12-Jul-2013	 	Pending	 		 	
	03.0099.BE	 	PCT	 	Belgium	 	EP Validation	 	24-Feb-2004	 	Granted	 	1 617 816	 	24-Feb-2024
	03.0099.CA	 	PCT	 	Canada	 	2517679	 	24-Feb-2004	 	Allowed	 	2517679	 	24-Feb-2024
	03.0099.EP	 	PCT	 	European Patent Convention	 	04785761.0	 	24-Feb-2004	 	Granted	 	1 617 816	 	24-Feb-2024
	03.0099.EP	 	DIV	 	European Patent Convention	 	08006465.2	 		 	Pending	 	1 938 803 A	 	24-Feb-2024

  
 14 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent /

Publication No.
	 	 Normal Expiry

Date

	03.0099.FR	 	PCT	 	France	 	EP Validation	 	24-Feb-2004	 	Granted	 	1 617 816	 	24-Feb-2024
	03.0099.DE	 	PCT	 	Germany	 	EP Validation	 	24-Feb-2004	 	Granted	 	1 617 816	 	24-Feb-2024
	03.0099.HU	 	PCT	 	Hungary	 	EP Validation	 	24-Feb-2004	 	Granted	 	E005977	 	24-Feb-2024
	03.0099.IE	 	PCT	 	Ireland	 	EP Validation	 	24-Feb-2004	 	Granted	 	1 617 816	 	24-Feb-2024
	03.0099.IT	 	PCT	 	Italy	 	EP Validation	 	24-Feb-2004	 	Granted	 	1 617 816	 	24-Feb-2024
	03.0099.JP	 	PCT	 	Japan	 	2006-532300	 	27-Feb-2004	 	Granted	 	4891774	 	27-Feb-2024
	03.0099.JP	 	DIV	 	Japan	 	2010-233858	 	27-Feb-2004	 	Granted	 	5548092	 	27-Feb-2024
	03.0099.ES	 	PCT	 	Spain	 	EP Validation	 	24-Feb-2004	 	Granted	 	1 617 816	 	24-Feb-2024
	03.0099.CH/LI	 	PCT	 	Switzerland / Liechtenstein	 	EP Validation	 	24-Feb-2004	 	Granted	 	1 617 816	 	24-Feb-2024
	03.0099.GB	 	PCT	 	United Kingdom	 	EP Validation	 	24-Feb-2004	 	Granted	 	1 617 816	 	24-Feb-2024

 A-1.4 “Controlled Release Compositions Comprising a Combination of Isosorbide Dinitrate and Hydralazine
Hydrochloride” 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent /
Publication No.
	 	 Normal Expiry

Date

								
	02.1007.US	 	CON	 	United States	 	13/606,915	 	7-Sep-2012	 	Granted	 	8,992,973	 	
	02.1007.US	 	CON2	 	United States	 	14/638,984	 	04-Mar-2015	 	Pending	 	—  	 	
	04.1007.CA	 	ORD	 	Canada	 	2627951	 	26-Oct-2006	 	Pending	 	2627951 A	 	26-Oct-2026
	04.1007.EP	 	ORD	 	European Patent Convention	 	20060826638	 	26-Oct-2006	 	Pending	 	1 951 210 A	 	26-Oct-2026

  
 15 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 A-1.5 “Multiparticulate Modified Release Composition” 

 

															
	 APIL Ref.
	  	 Case Type
	  	 Country
	  	 Application No.
	  	 Filing Date
	  	 Status
	  	 Patent /
Publication No.
	  	 Normal Expiry
Date

								
	 02.1816E.US
	  	CON2	  	United States	  	09/850,425	  	07-May-2001	  	Granted	  	6730325	  	1-Nov-2019
	 02.1816E.US
	  	CON4	  	United States	  	10/354,483	  	30-Jan-2003	  	Granted	  	6793936	  	1-Nov-2019
	 02.1816E.US
	  	CON5	  	United States	  	10/827,689	  	19-Apr-2004	  	Pending	  	2004-0197405	  	1-Nov-2019

 A-1.6 Case Number: 05.0082.US 

Invention Title: COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS 

 

																	
	 Country
	 	 Sub Case
	 	 Case Type
	 	 Status
	 	 Application Number
	 	 Filing Date
	 	 Patent Number
	 	 Issue Date
	 	 Expiration Date

									
	United States of America	 	2	 	ORD	 	Granted	 	10/268,928	 	11-Oct-2002	 	6,908,626	 	21-Jun-2005	 	25-Dec-2022

 A-1.7 Case Number: 06.0082. 

Invention Title: COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS 

 

																	
	Country	 	Sub Case	 	Case Type	 	Status	 	Application Number	 	Filing Date	 	Patent Number	 	Issue Date	 	Expiration Date
	Austria	 		 	EPC	 	Granted	 	02800993.4	 	11-Oct-2002	 	EP 1 443 912	 	29-Aug-2007	 	11-Oct-2022
	Belgium	 		 	EPC	 	Granted	 	02800993.4	 	11-Oct-2002	 	EP 1 443 912	 	29-Aug-2007	 	11-Oct-2022
	Bulgaria	 		 	EPC	 	Granted	 	02800993.4	 	11-Oct-2002	 	EP 1 443 912	 		 	11-Oct-2022
	Canada	 		 	PCT	 	Granted	 	2,463,495	 	11-Oct-2002	 	2,463,495	 	24-May-2011	 	11-Oct-2022
	Cyprus, Republic of	 		 	EPC	 	Granted	 	02800993.4	 	11-Oct-2002	 	EP 1 443 912	 	07-May-2010	 	11-Oct-2022
	Czech Republic	 		 	EPC	 	Granted	 	02800993.4	 	11-Oct-2002	 	EP 1 443 912	 		 	11-Oct-2022
	Denmark	 		 	EPC	 	Granted	 	02800993.4	 	11-Oct-2002	 	EP 1 443 912	 		 	11-Oct-2022
	Estonia	 		 	EPC	 	Granted	 	02800993.4	 	11-Oct-2002	 	EP 1 443 912	 		 	11-Oct-2022
	European Patent Convention	 		 	PCT	 	Granted	 	02800993.4	 	11-Oct-2002	 	EP 1 443 912	 	29-Aug-2007	 	11-Oct-2022
	Finland	 		 	EPC	 	Granted	 	02800993.4	 	11-Oct-2002	 	EP 1 443 912	 		 	11-Oct-2022
	France	 		 	EPC	 	Granted	 	02800993.4	 	11-Oct-2002	 	EP 1 443 912	 		 	11-Oct-2022
	Germany	 		 	EPC	 	Granted	 	02800993.4	 	11-Oct-2002	 	60222160.9	 		 	11-Oct-2022

  
 16 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

																	
	Greece				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Ireland				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Italy				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Japan		3		DIV		Published		2013-126534		11-Oct-2002						
	Luxembourg				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Monaco				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Netherlands				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Portugal				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Slovakia				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Spain				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Sweden				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Switzerland				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	Turkey				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022
	United Kingdom				EPC		Granted		02800993.4		11-Oct-2002		EP 1 443 912				11-Oct-2022

  
 17 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit A-2 

Nanotechnology Patents 
 [* * *] 

 

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent No.
	 	 Normal Expiry
Date

								
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]

  
 18 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 [* * *] 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent No.
	 	 Normal Expiry

Date

								
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent No.
	 	 Normal Expiry

Date

								
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent No.
	 	 Normal Expiry

Date

								
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]

  
 19 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 [* * *] 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent /

Publication No.
	 	 Normal Expiry

Date

								
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]

  
 20 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit A-3 

OCR Patents 
 [* * *] 

 

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent /

Publication No.
	 	 Normal Expiry
Date

								
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
 [* * *] 

 

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent /

Publication No.
	 	 Normal Expiry
Date

								
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]

  
 21 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit A-4 

Zogenix Patents 
 A-4.1 “Multiparticulate
Modified Release Composition” (hydrocodone ER) - US 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent /

Publication No.
	 	 Normal Expiry
Date

								
	02.1816E.US	 	CON	 	United States	 	09/566,636	 	08-May-2000	 	Granted	 	6228398	 	1-Nov-2019
	02.1816E.US	 	CON3	 	United States	 	10/331,754	 	30-Dec-2002	 	Granted	 	6902742	 	1-Nov-2019
	02.1816E.US	 	CIP	 	United States	 	11/372,857	 	10-Mar-2006	 	Pending	 	2006-0240105	 	1-Nov-2019

  
 22 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit A-5 

Palladin Patents 
 A-5.1 “Multiparticulate
Modified Release Composition” (hydrocodone ER) - Canada 
  

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent /

Publication No.
	 	 Normal Expiry
Date

								
	04.1816E.CA	 	PCT	 	Canada	 	2348871	 	01-Nov-1999	 	Granted	 	2348871	 	1-Nov-2019

  
 23 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit A-6 

Abuse Resistant Patents 
 [* * *] 

 

															
	 APIL Ref.
	 	 Case Type
	 	 Country
	 	 Application No.
	 	 Filing Date
	 	 Status
	 	 Patent /

Publication No.
	 	 Normal Expiry
Date

								
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]

  
 24 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit B-1 

Transferred Trademarks 
 B-1.1 “VERELAN”

  

													
	 APIL Ref.
	 	 Trademark
	 	 Country /

Territory
	 	 Application No.
	 	 Filing Date
	 	 Registration No.
	 	 Registration

Date

							
	TM.0039.US	 	VERELAN	 	United States	 	73/760,372	 	28-Oct-1988	 	1551582	 	15-Aug-1989
	TM.0039.CA	 	VERELAN	 	Canada	 	670059	 	07-Nov-1990	 	TMA 443175	 	26-May-1995
	TM.0039.KR	 	VERELAN	 	South Korea	 	185382	 	14-Dec-1989	 	40-0185382	 	14-Dec-1989
	TM.0039.TW-2	 	VERELAN	 	Taiwan	 	97047657	 	15-Oct-2008	 	01367514	 	01-Jul-2009

  
 25 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit B-2 

Licensed Trademarks 
 B-2.1
“NANOCRYSTAL” 
  

													
	 APIL Ref.
	 	 Trademark
	 	 Country /

Territory
	 	 Application No.
	 	 Filing Date
	 	 Registration No.
	 	 Registration

Date

							
	TM.0001.US-1	 	NANOCRYSTAL	 	United States	 	75/425,869	 	29-Jan-1998	 	2492925	 	25-Sep-2001
	TM.0001.US-2	 	NANOCRYSTAL	 	United States	 	75/425,872	 	29-Jan-1998	 	2386089	 	12-Sep-2000
	TM.0001.CA	 	NANOCRYSTAL	 	Canada	 	732238	 	30-Jun-1993	 	TMA 504715	 	27-Nov-1998
	TM.0001.CTM	 	NANOCRYSTAL	 	European Union	 	000885079	 	22-Jul-1998	 	000885079	 	12-May-2000
	TM.0001.JP-1	 	NANOCRYSTAL	 	Japan	 	63822/98	 	29-Jul-1998	 	4398178	 	07-Jul-2000
	TM.0001.JP-2	 	NANOCRYSTAL	 	Japan	 	H10-071844	 	25-Aug-1998	 	4374459	 	07-Apr-2000
	TM.001.JP-3	 	NANOCRYSTAL	 	Japan	 	105670199	 	19-Nov-1999	 	4428472	 	27-Oct-2000

 B-2.2 “SODAS” 

 

													
	 APIL Ref.
	 	 Trademark
	 	 Country /

Territory
	 	 Application No.
	 	 Application

Date
	 	 Registration No.
	 	 Registration

Date

							
	TM.0015.US	 	SODAS	 	United States	 	78/127,040	 	08-May-2002	 	2794607	 	16-Dec-2003
	TM.0015.AR	 	SODAS	 	Argentina	 	2058068	 	29-Mar-1999	 	1724388 [2365412]	 	30-Oct-1999
	TM.0015.CA	 	SODAS	 	Canada	 	1006507	 	24-Feb-1999	 	TMA 531496	 	21-Aug-2000
	TM.0015.CTM	 	SODAS	 	European Union	 	0002012953	 	21-Dec-2000	 	0002012953	 	02-Apr-2002
	TM.0015.IE	 	SODAS	 	Ireland	 	3290/87	 	25-Sep-1987	 	125699	 	25-Sep-1987

  
 26 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 B-2.3 “CODAS” 
  

															
	 Country /

Territory
	 	 Trademark
	 	 ALKS Ref
	 	 Application No
	 	 Registration

No.
	 	 Status
	 	 Filing Date
	 	 Registration

Date

	United States
of America	 	CODAS	 	TM.0013.US	 	78538974	 	3591236	 	Registered	 	28-Dec-2004	 	17-Mar-2009

 B-2.4 “BeadTek” 

 

															
	 Trademark
	 	 ALKS Ref
	 	 Application

No
	 	 Registration No.
	 	 Status
	 	 Country /

Territory
	 	 Filing Date
	 	 Registration

Date

	BEADTEK	 	TM.0202.US	 	86452063	 	—  	 	Pending	 	United States	 	12-Nov-2014	 	—  
	BEADTEK
(design)	 	 	 	86530165	 	—  	 	Pending	 	United States	 	10 Feb 2015	 	—  

  
 27 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit C 

Transferred License and Settlement Agreements 
 [*
* *] 

  
 28 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Exhibit D to Agreement 

Earn-Out Consideration 
  

	 	ARTICLE 1	Definitions. 

 The following terms shall have the following meaning for this
Exhibit D; and terms used, but not defined in this Exhibit D, shall have the meanings set forth in the remainder of the Agreement. 

(a) “Ancillary Agreements” shall have the meaning set forth in the Purchase Agreement. 

(b) “Business Day” shall mean any day that is not a Saturday, a Sunday or other day on which commercial banks in the City of
New York, New York or Dublin, Ireland are required or authorized by Law to be closed. 
 (c) “Closing” shall have the
meaning set forth in the Purchase Agreement. 
 (d) “Commercially Reasonable Efforts” shall mean, with respect to the
efforts to be expended by Purchaser and its Affiliates, licensees and sublicensees with respect to the Development Milestones and Commercial Milestones, reasonable, diligent, good faith efforts to accomplish any such Development Milestones and
Commercial Milestones as is commonly used in the pharmaceutical industry generally to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the research, development and commercialization of
any Earn-Out Product, such efforts shall be substantially equivalent to those efforts and resources commonly used in the pharmaceutical industry generally by a pharmaceutical company for a product owned by it or to which it has rights, which product
is at a similar stage in its development and is of similar market potential taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the
product, the likelihood of regulatory approval, the profitability and commercial potential of the product, but without regard to any Earn-Out Consideration payable under this Exhibit D. 

(e) “Divestiture” (and other correlative terms) shall mean any transaction in which any
Earn-Out Product or any intellectual property assets related to the same are divested or transferred by any means, including by way of merger, consolidation, asset acquisition or sale, license, sublicense,
purchase, sale, assignment or other similar transfer. 
 (f) “Earn-Out Consideration” shall mean, collectively,
(i) Development Milestone Earn-Out Consideration, (ii) Commercial Milestone Earn-Out Consideration, and (iii) Net Sales
Earn-Out Consideration. 
 (g) “Earn-Out Product Patents” shall mean (i) the
Nanotechnology Patents, (ii) the Meloxicam Transferred Patents, (iii) the OCR Patents and (iv) all Patents of Purchaser and its Affiliates, licensors, licensees or sublicensees that claim an
Earn-Out Product or manufacture or use thereof, together with all Patents that claim priority (in whole or in part, directly or indirectly) with any of the foregoing of clauses (i), (ii), (iii) or (iv).

 (h) “Earn-Out Products” shall mean (i) Meloxicam IV/IM, (ii) Meloxicam Parenteral Formulation and
(ii) any other product discovered or identified using the Nanotechnology IP, the OCR IP or the Meloxicam Transferred Patents, and that contains the same active pharmaceutical ingredient as Meloxicam IV/IM (including any salts or other
versions of such active pharmaceutical ingredient). 
 (i) “FDA” shall mean the United States Food and Drug Administration
and any successor agency thereto. 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (j) “First Commercial Sale” shall mean, on an Earn-Out Product-by-Earn-Out
Product and country-by-country basis, the first commercial sale in an arms’ length transaction of an Earn-Out Product to a Third Party by Purchaser or any of its Affiliates, licensees or sublicensees in such country following Regulatory
Approval of such Earn-Out Product in such country. 
 (k) “GAAP” shall mean generally accepted accounting principles in the
United States. 
 (l) “Governmental Entity” shall mean any court, administrative agency, commission or other governmental
authority, body or instrumentality, federal, state, local, domestic or foreign governmental or regulatory authority. 
 (m)
“IND” shall mean an investigational new drug application filed with the FDA, the competent authorities of a European Union member state, or equivalents in other countries or regulatory jurisdictions for authorization to commence
clinical studies of a pharmaceutical product. 
 (n) “Know-How” shall mean all proprietary data, information, knowledge,
know-how, inventions, discoveries, trade secrets, processes, techniques, strategies, methods, practices, skills, experience, documents, apparatus, devices, assays, screens, databases (including safety databases), database structures and data
analysis methods, compositions, materials, methods, formulas, improvements, clinical and non-clinical study reports, test data including pharmacological, biological, chemical, biochemical, toxicological, and clinical test data, analytical and
quality control data, stability data, studies and procedures. 
 (o) “Law” shall mean any United States federal, state or
local, or any non-United States law, statute, ordinance, rule, regulation, judgment, order, injunction, decree, arbitration award, agency requirement, license or permit of any Governmental Entity. 

(p) “Liens” shall mean all liens, pledges, mortgages, charges, claims, security interests, restrictions on transfer,
encroachments or encumbrance, but not including any license(s) of Transferred IP. 
 (q) “MAA” shall mean a Marketing
Authorization Application as defined in EU Directive 2001/83/EC and EU Regulation (EC) No. 726/2004. 
 (r) “Meloxicam
Transferred Patents” shall mean the Transferred Patents with respect to the patents and patent applications listed in subsections A-1.1, A-1.2 and A-1.3 of Exhibit A-1. 

(s) “NDA” shall mean a New Drug Application or Supplemental New Drug Application filed with the FDA. 

(t) “Net Sales” shall mean, consistent with GAAP: 

(i) Subject to clause (ii) of this definition, the aggregate gross amount invoiced to unrelated Third Parties by Purchaser, its
Affiliates, its licensees and its sublicensees for the sale of Earn-Out Products, less to the extent applicable to such sale: (A) trade, cash and quantity discounts, if any, actually accrued or paid; (B) credits, allowances and adjustments
actually accrued or paid to customers, including credits for rejected or returned Earn-Out Products previously sold; (C) freight, insurance and other transportation costs actually accrued or paid, to the extent separately identified on the
invoice; (D) rebates or reimbursements actually accrued or paid to managed health care organizations, national, federal, state, or local governments (or their agencies), and managed health organizations (including Medicaid rebates), and
(E) taxes, including value added taxes (VAT) (other than taxes on Purchaser’s, its Affiliates’, its licensees’ or its sublicensees’ income), customs duties or other governmental charges on sales or use actually paid by
Purchaser, its Affiliates, its licensees or its sublicensees with respect to the sale of such Earn-Out Products. No fines, penalties or comparable payments to national, federal, state, or local governments (or their agencies) or to other third
parties shall be deductible from Net Sales. 

  
 30 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (ii) Sales between Purchaser, its Affiliates, its licensees or its sublicensees shall be
disregarded for the purposes of calculating Net Sales as long as the Earn-Out Products are (A) resold to an unrelated Third Party in which case the final sale to such unrelated Third Party shall be included in Net Sales or (B) transferred
or disposed of by Purchaser, its Affiliates, its licensees or its sublicensees for a purpose specified in clause (i) of this definition. Transfers or dispositions of Earn-Out Products, where on a non-profit basis and in line with normal
industry practice, (1) for charitable purposes; (2) for preclinical, clinical trial, or non-commercial manufacturing purposes; or (3) for regulatory or governmental purposes shall not in each case be deemed “sales” for the
purposes of calculating Net Sales. In addition, transfers or dispositions of free promotional samples of Earn-Out Products in line with normal industry practice shall not be deemed “sales” for the purposes of calculating Net Sales.
Otherwise, for the purposes of calculating Net Sales, a “sale” shall include any transfer or other disposition of any Earn-Out Product for consideration. 

With respect to sales of Earn-Out Products invoiced in U.S. dollars, Net Sales shall be determined in U.S. dollars. With respect to sales of
Earn-Out Products invoiced in a currency other than U.S. dollars, Net Sales shall be determined by converting the currencies in which the sales are made into U.S. dollars, at rates of exchange determined in a manner consistent with Purchaser’s,
its Affiliates’, its licensees’ or its sublicensees’, as applicable, method for calculating rates of exchange in the preparation of such entity’s annual financial statements in accordance with GAAP consistently applied. No amount
for which deduction is permitted pursuant to this definition shall be deducted more than once. 
 (u) “Net Sales Earn-Out
Consideration Term” shall mean, on an Earn-Out Product-by-Earn-Out Product and country-by-country basis, the period of time commencing upon the First Commercial Sale of an Earn-Out Product and ending upon the later of (i) the fifteenth
(15th) anniversary of the First Commercial Sale of such Earn-Out Product in such country, and (ii) the date of the last to expire Valid Claim of an Earn-Out Product Patent covering such
Earn-Out Product in such country. 
 (v) “Patents” shall mean any and all patents and patent applications (which for
purposes of this Agreement shall include certificates of invention and applications for such certificates), including any divisionals, continuations, continuations-in-part, substitutions, reissues, re-examinations, revalidations, extensions
(including pediatric exclusivity patent extensions), registrations, supplementary protection certificates, renewals, and foreign equivalents of any such patents or patent applications. 

(w) “Person” shall mean a person, corporation, partnership, limited liability company, joint venture, trust or other entity
or organization. 
 (x) “Regulatory Approval” shall mean, with respect to a country or extra-national territory, all
approvals, licenses, registrations or authorizations of any Regulatory Authority necessary in order to commercially distribute, sell or market a drug product in such country or some or all of such extra-national territory. 

(y) “Regulatory Authority” shall mean any supra-national, federal, national, regional, state, provincial or local
governmental regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the development, manufacture and commercialization of drug products, including
the FDA. 
 (z) “Regulatory Materials” shall mean regulatory applications, submissions, notifications, registrations, or
other filings made to or with a Regulatory Authority that are necessary or reasonably desirable in order to develop, manufacture, market, sell or otherwise commercialize a product in a particular country or regulatory jurisdiction. Regulatory
Materials include INDs, MAAs and NDAs (as applications, but not the approvals with respect thereto). 
 (aa) “Third Party”
shall mean, as of any relevant time, any Person who is not an Affiliate of Purchaser. 

  
 31 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (bb) “United States” or “U.S.” shall mean the United States
of America, including its territories and possessions, the District of Columbia and Puerto Rico. 
 (cc) “Valid Claim”
shall mean a claim of an issued or pending Patent which claim (i) in the case of an issued Patent, has not been found to be unpatentable, invalid or unenforceable by a court or other authority of competent jurisdiction, from which decision no
appeal is taken or can be taken and which otherwise has not been dedicated to the public or finally disclaimed, and (ii) in the case of a pending Patent, a Valid Claim shall not include a claim in a pending Patent that has a filing date or an
earliest claimed priority date that is more than five (5) years prior to the date upon which pendency of the pending Patent is determined. 

Definitions for each of the following terms are found in this Exhibit D as indicated below: 

 

			
	 Defined Term
	  	 Location

	Assigned Reversion IP Assets	  	Section 4.2(c)
	Assigned Reversion Know-How	  	Section 4.2(c)
	Assigned Reversion Patents	  	Section 4.2(c)
	Challenge Period	  	Section 4.1(b)
	Commercial Milestone Earn-Out Consideration	  	Section 2.1(b)(i)
	Commercial Milestones	  	Section 2.1(b)(i)
	Cure Period	  	Section 4.1(c)
	Development Milestone Earn-Out Consideration	  	Section 2.1(a)(i)
	Development Milestones	  	Section 2.1(a)(i)
	Disagreement Notice	  	Section 4.1(b)
	Divested Assets	  	Section 2.4
	NDA Requirement	  	Section 3.1
	Net Sales Earn-Out Consideration	  	Section 2.1(c)(i)
	Net Sales Report	  	Section 2.2
	Reversion Date	  	Section 4.1(d)
	Reversion Event	  	Section 4.1(a)
	Reversion Material	  	Section 4.2(j)
	Reversion Notice	  	Section 4.1(b)
	Transferee	  	Section 2.4

  

	 	ARTICLE 2	Earn-Out Consideration. 

 2.1 Earn-Out Consideration. 

(a) Development Milestone Earn-Out Consideration. 

(i) The following amounts (“Development Milestone Earn-Out Consideration”) shall be payable in accordance with
Section 5 of the Agreement and this Exhibit D upon achievement of the following events (“Development Milestones”) by Purchaser and its Affiliates, licensees and sublicensees, and shall be non-refundable and
non-creditable and not subject to deduction or set-off: 
  

			
	 Development Milestone
	  	 Amount of Development Milestone
Earn-Out
Consideration (U.S. Dollars)

	 [* * *]
	  	$[* * *]
	 [* * *]
	  	$[* * *]

 (ii) Purchaser shall notify and pay to APIL each Development Milestone Earn-Out Consideration within thirty
(30) calendar days after the occurrence of the corresponding Development Milestone. Each such payment shall be made by wire transfer of immediately available funds to such account or accounts as are designated in writing by APIL. 

  
 32 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (b) Commercial Milestone Earn-Out Consideration. 

(i) The following amounts (“Commercial Milestone Earn-Out Consideration”) shall be payable in accordance with Section 5
of the Agreement and this Exhibit D following the first calendar year during which the aggregate annual Net Sales of Earn-Out Products by Purchaser and its Affiliates, licensees and sublicensees first exceed the threshold amounts set
forth in the table below (“Commercial Milestones”), and shall be non-refundable and non-creditable and not subject to deduction or set-off: 
  

			
	 Commercial Milestones
	  	 Amount of Commercial Milestone
Earn-Out
Consideration (U.S. Dollars)

	 $[* * *] in annual Net Sales
	  	$[* * *]
	 $[* * *] in annual Net Sales
	  	$[* * *]
	 $[* * *] in annual Net Sales
	  	$[* * *]

 (ii) Purchaser shall notify and pay to APIL each Commercial Milestone Earn-Out Consideration within thirty
(30) calendar days after the end of the calendar quarter in which the corresponding Commercial Milestone is achieved. Each such payment shall be made by wire transfer of immediately available funds to such account or accounts as are designated
in writing by APIL. 
 (c) Net Sales Earn-Out Consideration. 

(i) During the Net Sales Earn-Out Consideration Term, Purchaser shall pay in accordance with Section 5 of the Agreement and this
Exhibit D an amount of [* * *] percent ([* * *]%) of the aggregate Net Sales of Earn-Out Products (“Net Sales Earn-Out Consideration”), which amount shall be non-refundable and non-creditable and not subject to deduction
or set-off. 
 (ii) If, pursuant to Section 2.1(c)(i) of this Exhibit D, any Net Sales Earn-Out Consideration is payable
on Net Sales of an Earn-Out Product in the U.S. and there is no Valid Claim of an Earn-Out Product Patent in the U.S. covering such Earn-Out Product at the time of such sale, the percentage applicable to calculate such Net Sales Earn-Out
Consideration shall be reduced by thirty percent (30%) from the percentage set forth in Section 2.1(c)(i) of this Exhibit D. 

2.2 Net Sales Reports. During the Net Sales Earn-Out Consideration Term, (a) within five (5) Business Days after the end of
each calendar quarter, Purchaser shall provide an estimate of the Net Sales, on a Earn-Out Product-by-Earn-Out Product and country-by-country basis, to APIL for the preceding calendar quarter and (b) within forty-five (45) calendar days
after the end of each calendar quarter, Purchaser shall provide a sales report (“Net Sales Report”), on a Earn-Out Product-by-Earn-Out Product and country-by-country basis, to APIL showing a reconciliation of gross sales to Net Sales of
each Earn-Out Product during such calendar quarter reporting period (including the related permitted deductions) and the Net Sales Earn-Out Consideration payable with respect thereto. Purchaser shall pay to APIL the Net Sales Earn-Out Consideration
for each calendar quarter at the time of submission of the corresponding Net Sales Report. If no Net Sales Earn-Out Consideration is due for any period hereunder following commencement of the reporting obligation, Purchaser shall so report. 

2.3 Late Payments. If APIL does not receive payment of any sum due to them on or before the due date, simple interest shall thereafter
accrue on the sum due to APIL until the date of payment at the per annum rate of two percent (2%) over the then-current prime rate quoted by Citibank in New York City or the maximum rate allowable by applicable Law, whichever is lower. 

  
 33 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 2.4 Divestitures. If at any time after the Effective Date, Purchaser Divests to a
Third Party or an Affiliate any Earn-Out Product, Earn-Out Product Patent or any other intellectual property asset related to an Earn-Out Product (collectively, “Divested Assets” and the party receiving any Divested Assets the
“Transferee”), Purchaser shall: (a) make provision for the Transferee to assume and succeed to the obligations of Purchaser set forth in this Exhibit D; and (b) prior to or simultaneously with the consummation
of any such Divestiture, cause such Transferee to provide to APIL an instrument of assumption in a reasonable form for the benefit of APIL effecting the assumption and succession described in the foregoing Clause (a), and proof satisfactory to
APIL of such Transferee’s financial capacity to assume Purchaser’s obligations set forth in this Exhibit D. Purchaser shall remain liable to APIL for all obligations set forth in this Exhibit D following any such
Divestiture. 
  

	 	ARTICLE 3	Diligence; Reporting; Audit. 

 3.1 Diligence. Purchaser, itself or through one or
more of its Affiliates, licensees and sublicensees, shall use Commercially Reasonable Efforts to achieve each of the Development Milestones and Commercial Milestones. Without limiting the foregoing, Purchaser, itself or through one or more of its
Affiliates, licensees and sublicensees, shall file an NDA for an Earn-Out Product with the FDA on or before [* * *] (the “NDA Requirement”). 

3.2 Reporting. 
 (a) For
so long as any Earn-Out Product is in development, on each anniversary of the Effective Date, Purchaser shall provide a written report to APIL detailing the development activities with respect to the Earn-Out Products completed for the past annual
reporting period and anticipated to be undertaken for the next twelve (12) months period. At a minimum, such report shall include a list and general status (i.e., what stage in discovery/development using Purchaser’s internal measures) of
each Earn-Out Product then in development, and any ongoing pre-clinical or clinical activities (including initiations and cessations) and results, and submission and approvals to or from Regulatory Authorities (including anticipated date of
achievement of the Development Milestones), and any other similar information relating to development activities for the Earn-Out Products. Purchaser shall cause its senior officers from its research and clinical development operations to be
reasonably available to APIL to answer questions related to the matters required to be discussed in each report. 
 (b) For so long as any
Earn-Out Product is being marketed, sold, or otherwise commercialized, within sixty (60) days of the end of each calendar quarter, Purchaser shall provide a written report to APIL detailing the commercialization efforts with respect to the
Earn-Out Products completed for the past quarterly reporting period and anticipated to be undertaken for the next calendar quarter and for the three (3) calendar quarters thereafter. At a minimum, such report shall include with respect to the
commercialized Earn Out Products marketing and sales efforts, forecasted sales, pricing changes, anticipated date of achievement of the Commercial Milestones, and any other similar information relating to commercialization activities for the
Earn-Out Products. Purchaser shall cause its senior officers from business operations to be reasonably available to APIL to answer questions related to the matters required to be discussed in each report. 

3.3 Audit. Purchaser shall maintain, and shall cause its Affiliates, licensees and sublicensees to maintain, complete and accurate
books and records in sufficient detail to permit APIL, at its expense, to confirm the achievement of Development Milestones and Commercial Milestones, and the calculation of Earn-Out Consideration payable under this Agreement and this
Exhibit D. Upon reasonable prior notice, such books and records shall be open during regular business hours for a period of three (3) years from the creation of individual books and records for examination, by an independent
certified public accountant selected by APIL and reasonably acceptable to Purchaser for the sole purpose of verifying for APIL the accuracy of the financial statements, reports and notices furnished by Purchaser pursuant to this Agreement and this
Exhibit D, and of any payments made, or required to be made, by Purchaser to APIL pursuant to this Agreement and this Exhibit D. Any amounts shown to be owed to APIL but unpaid shall be paid by Purchaser within thirty
(30) days after the accountant’s report, plus interest (as set forth in Section 2.3 of this Exhibit D) from the original due date. If Purchaser is found to have 

  
 34 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
underpaid amounts owed to APIL by five percent (5%) or more, then Purchaser shall also pay for the conduct of the audit. In the event that Purchaser has overpaid APIL, at APIL’s option,
Purchaser shall either credit the amount of any such overpayment to amounts subsequently due by Purchaser to APIL under this Exhibit D or APIL shall reimburse Purchaser the amount of any such overpayment. 

 

	 	ARTICLE 4	Reversion. 

 4.1 Determination of Reversion Event. 

(a) A “Reversion Event” shall exist in the event that Purchaser, itself or through one or more of its Affiliates, licensees
and sublicensees, (i) fails to satisfy the NDA Requirement, or (ii) in the reasonable judgment of APIL, fails to comply with its Commercially Reasonable Efforts requirements under Section 3.1 of this Exhibit D; provided
that, any such failure is not attributable to the material breach by APIL or any of its Affiliates of any of the Ancillary Agreements, which material breach was noticed by Purchaser prior to its receipt of a Reversion Notice from APIL under this
Section 4.1. 
 (A) In the event the failure to satisfy the NDA Requirement is the result of a change in the FDA’s policies or
procedures regarding the approval of the Earn-Out Product or drugs in the same class as the Earn-Out Product, and Purchaser, its Affiliates, licensees or sublicensees have used Commercially Reasonable Efforts to accommodate such change and were
still unable to satisfy the NDA Requirement, then the deadline shall be extended for a reasonable period of time, but not more than three-hundred sixty-five (365) calendar days or such longer period of time as determined by APIL in good faith
based on the impact of such change in the FDA’s policies or procedures on their ability to accommodate such change in policies or procedures. (B) In the event the failure to satisfy the NDA Requirement is the result of other delays or
circumstances that are outside of the reasonable control of Purchaser or its Affiliates, licensees and sublicensees, and Purchaser, its Affiliates, licensees or sublicensees have used Commercially Reasonable Efforts consistent with Section 3.1
of this Exhibit D to overcome such delay or circumstance, then APIL will reasonably consider extending the deadline for a reasonable period of time, but not more than three-hundred sixty-five (365) days, to overcome such failure. In each
case of (A) or (B), the compliance with such new deadline shall remain an obligation of Purchaser, its Affiliates, licensees or sublicensees subject to their diligence efforts under Section 3.1 of this Exhibit D and APIL’s
rights under this Section 4.1(a). 
 (b) Upon a Reversion Event, APIL shall provide Purchaser with written notice of such Reversion
Event (a “Reversion Notice”). If Purchaser disagrees with APIL regarding the existence of a Reversion Event, it shall notify APIL within ten (10) Business Days of receipt of a Reversion Notice of its disagreement (such period,
the “Challenge Period,” and such notice, a “Disagreement Notice”). For a period of thirty (30) Business Days following the delivery of such Disagreement Notice, Purchaser and APIL shall seek in good faith to
come to an agreement on the existence of the Reversion Event. If at the end of such thirty (30) Business Day period Purchaser and APIL have not reached an agreement, they shall jointly select an independent mediator, free of any conflict with
either party, having the requisite licensing and pharmaceutical industry experience to render a decision regarding the existence of a Reversion Event, and selected from a panel of persons experienced in the pharmaceutical and life sciences
industries provided by Judicial Administration and Arbitration Services or its successor (“JAMS”). If the parties do not agree on an independent mediator within five (5) Business Days of initiating mediation under this
Section 4.1(b), the independent mediator shall be selected by JAMS in accordance with its rules. Each party shall prepare and submit a written summary of such party’s position, which shall not exceed twenty-five (25) pages, and
any relevant evidence in support thereof to the independent mediator within ten (10) Business Days of the selection of the independent mediator. Upon receipt of such summaries from both parties, the independent mediator shall provide copies of
the same to the other party. The independent mediator shall be authorized to solicit briefing or other submissions on particular questions and to set specific page limits for such additional briefing and submissions. Within five (5) Business
Days of the delivery of such summaries by the independent mediator, each party shall submit a written rebuttal of the other party’s summary and may also amend and re-submit its original summary, with each party’s response to include a
supporting explanation of why its 

  
 35 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
proposed terms are more appropriate than the other party’s proposed terms and any documentary evidence in support thereof. Oral presentations shall not be permitted unless otherwise
requested by the independent mediator. Only if so permitted, a neutral location of any such oral presentations shall be selected by the independent mediator. The independent mediator shall make a final decision with respect to the arbitration matter
within ten (10) Business Days following receipt of the last of such rebuttal statements submitted by the parties, and shall make a determination by selecting the resolution proposed by one of the parties that as a whole is the most fair and
reasonable to the parties in light of the totality of the circumstances, and shall provide the parties with a written statement setting forth the basis of the determination in connection therewith. For clarity, the independent mediator shall only
have the right to select a resolution proposed by one of the parties in its entirety and without modification. The decision of the independent mediator shall be controlling regarding the existence of a Reversion Event. Purchaser and APIL shall bear
the costs of the independent mediator equally. 
 (c) If the existence of a Reversion Event, other than one that involves a failure to
satisfy the NDA Requirement, is confirmed, through (i) Purchaser’s non-delivery of a Notice of Disagreement or (ii) through the determination of an independent mediator, Purchaser, itself or through one or more of its Affiliates,
licensees or sublicensees shall have the right to cure such Reversion Event for a period of four (4) months from the determination of such Reversion Event (such period, the “Cure Period”) and, if it elects to exercise such
right, shall notify APIL in writing of the same. In the case that such Reversion Event is cured in APIL’s reasonable judgment during or by the end of the Cure Period, such Reversion Event shall no longer exist and APIL shall not have the right
to invoke any other rights under this Article 4 in connection with such event that would have remained a Reversion Event but for such cure. 

(d) For purposes of this Article 4, the “Reversion Date” shall be (i) the date on which the Challenge Period
expires without Purchaser having sent a Disagreement Notice to APIL, unless the Reversion Event at issue qualifies for a right to cure pursuant to Section 4.1(c) of this Exhibit E and Purchaser has elected to exercise such right to cure
in which case clause (d)(iii) below shall apply, (ii) where the Reversion Event involves a failure to satisfy the NDA Requirement and Purchaser has sent a Disagreement Notice in connection therewith, the date on which the parties agree, or the
independent mediator issues its determination, that such Reversion Event has occurred, or (iii) where the Reversion Event does not involve a failure to satisfy the NDA Requirement, and Purchaser has elected its right to cure pursuant to
Section 4.1(c) of this Exhibit D, the date on which the Cure Period expires without Purchaser having cured such Reversion Event to APIL’s reasonable satisfaction. 

4.2 Events Upon Determination of a Reversion Event. 

(a) On the Reversion Date, all licenses and other rights of Purchaser and its Affiliates, licensees and sublicensees under this Agreement
(i) with respect to the Nanotechnology IP shall automatically terminate in their entirety, and (ii) with respect to the OCR IP shall automatically terminate solely in regards to the Earn-Out Products. 

(b) As of the Reversion Date, but subject to Sections 4.2(h), 4.2(i) and 4.2(j), Purchaser, and its Affiliates, licensees and
sublicensees shall cease all research, development, manufacture, sales, offers to sell, use, importation and commercialization of the Earn-Out Products. 

(c) Promptly following the Reversion Date, Purchaser shall (i) assign to APIL the Meloxicam Transferred Patents and any other Patents
owned or controlled by it and its Affiliates, licensees or sublicensees solely relating to the Earn-Out Products (collectively, the “Assigned Reversion Patents”), and (ii) transfer to APIL all Know-How owned or controlled by it
and its Affiliates, licensees or sublicensees solely relating to the Earn-Out Products (the “Assigned Reversion Know-How” and together with the Assigned Reversion Patents, the “Assigned Reversion IP Assets”). 

(d) As of the Reversion Date, Purchaser grants to APIL a non-exclusive, worldwide license (sublicenseable through multiple tiers) under all
Patents and Know-How owned or controlled by Purchaser and its 

  
 36 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Affiliates, licensees or sublicensees (other than Assigned Reversion Patents and Assigned Reversion Know-How) that are practiced by or on behalf of Purchaser and its Affiliates, licensees and
sublicensees as of the Reversion Date that are necessary or useful to research, develop, manufacture, sell, offer to sell, use, import or otherwise commercialize any of the Earn-Out Products. 

(e) Promptly following the Reversion Date, Purchaser shall assign to APIL all right, title and interest in and to those trademarks used
exclusively with the Earn-Out Products, excluding any such trademarks that include, in whole or part, any corporate name or logo of Purchaser or its Affiliates. 

(f) Promptly following the Reversion Date, Purchaser shall (i) transfer and assign to APIL all Regulatory Materials and Regulatory
Approvals relating to the Earn-Out Products, or, if not possible, grant to APIL an exclusive right of reference thereunder. 
 (g) To the
extent that any payments would be owed by Purchaser to any Third Party under any agreement with such Third Party that is applicable to the exercise by APIL of any (sub)license, right of reference or other right provided in this Section 4.1,
Purchaser shall notify APIL of the existence and anticipated amounts of such payments and APIL shall have the right either to decline such (sub)license, right of reference or other right provided in this Section 4.1 or to take the same, in
which case APIL agrees to comply with any obligations under such agreement of Purchaser that apply to APIL and of which APIL was informed by Purchaser and to make such payments. 

(h) Promptly following the Reversion Date and as requested by APIL, Purchaser shall, and shall cause its Affiliates, licensees and
sublicensees to, (i) wind up the performance of any clinical trials for Earn-Out Products ongoing as of the Reversion Date, or (ii) transfer and assign to APIL, to the extent assignable by Purchaser in accordance with applicable Law, the
management and continued performance of any clinical trials for Earn-Out Products ongoing as of the Reversion Date (provided that if the management and continued performance thereof is not assignable, then at the request of APIL, Purchaser shall,
and shall cause its Affiliates, licensees and sublicensees to, continue to manage and perform such clinical trial(s) for a limited time period at the direction of APIL) the reasonable and documented out-of-pocket cost of which that is incurred after
the Reversion Date shall be borne by APIL. 
 (i) Promptly following the Reversion Date and as requested by APIL, Purchaser shall assign to
APIL any agreements with third party suppliers covering the supply or sale of the Earn-Out Products, or, if such agreements cover other products or do not permit assignment under their terms, then, to enable APIL to qualify an alternate, validated
source of supply, Purchaser shall supply finished Earn-Out Products for a reasonable period (not to exceed six (6) months) and at a cost equal to the cost of goods for any such Earn-Out Product calculated in accordance with industry standards
(including overhead) plus [* * *]. 
 (j) As of the Reversion Date, if Purchaser or any of its and its Affiliates, licensees or sublicensees
have any inventory of Earn-Out Product, or any components thereof, suitable for use in clinical trials or for commercialization (“Reversion Material”), Purchaser and its Affiliates, licensees and sublicensees shall offer in writing
to sell the Reversion Material to APIL at Purchaser’s or the applicable Affiliate’s, licensee’s or sublicensee’s fully-allocated cost of manufacturing, and APIL shall have the option (but no obligation) to purchase the same by
responding in writing to such offer within thirty (30) days. If APIL does not exercise such option, Purchaser and its Affiliates, licensees or sublicensees shall be entitled to sell any such Reversion Material, subject to any Earn-Out
Consideration applicable to such sale pursuant to the terms and conditions of this Exhibit D. 
 4.3 Without limiting the
generality of this Article 4, any assignment, transfer, license or other right made or granted to APIL pursuant to this Article 4 shall be effected without any consideration payable by APIL. 

  
 37 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 4.4 Without limiting the generality of this Article 4, following the assignment and transfer
under Section 4.2(c), (a) Purchaser shall have no right to use any of the Assigned Reversion IP Assets; (b) APIL shall have at its expense the sole and exclusive right to prosecute, maintain, defend and enforce all Assigned Reversion
Patents assigned to APIL pursuant to such Section 4.2(c), and for purposes of all those activities, (i) APIL shall be treated as the owner of such Assigned Reversion Patents, and shall be solely responsible for the costs associated with
such activities and shall have the sole right to retain any and all recoveries resulting from such activities, and (ii) to the extent required by applicable Law, at the cost of APIL, Purchaser shall, and shall cause each of its Affiliates,
licensees and sublicensees to, join any suit or proceeding regarding any such Assigned Reversion Patents, or designate APIL (or an Affiliate thereof) as such party’s authorized agent for such Assigned Reversion Patents. 

4.5 Purchaser shall ensure that Purchaser receives from any of its licensees and sublicensees all rights necessary for Purchaser to effectuate
the assignments and transfers to APIL and to grant to APIL the rights and licenses set forth in this Article 4. 
 4.6 Purchaser shall not,
and shall ensure that its Affiliates shall not, grant any Lien in or to any Assigned Reversion IP Assets, or take any action or commit any omission that may adversely affect or in any way impair, interfere with or prevent APIL’s right to
receive the benefit of the assignments, transfers and licenses granted under this Article 4. 
 4.7 The right of reversion hereunder shall
be APIL’s sole and exclusive remedy for Purchaser’s failure to satisfy the NDA Requirement or failure to comply with its Commercially Reasonable Efforts requirements under Section 3.1 of this Exhibit D, provided the
foregoing shall in no way limit APIL’s right to collect and be paid any Earn-Out Consideration based on Development Milestones or Commercial Milestones achieved as of the Reversion Date, or on sales of the Earn-Out Products prior to the
Reversion Date or permitted thereafter pursuant to Section 4.2(j). 

  
 38EX-10.6

 Exhibit 10.6 

EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 TRANSITION SERVICES AGREEMENT 

This TRANSITION SERVICES AGREEMENT (this “Agreement”), dated as of April 10, 2015, is made by and among Alkermes Pharma
Ireland Limited, a private limited company incorporated in Ireland (“Supplier”), Recro Pharma, Inc., a Pennsylvania corporation (“Recipient Representative”), DV Technology LLC, a Delaware limited liability company
(the “Company”), and Alkermes Gainesville LLC, a Massachusetts limited liability company (“Alkermes Gainesville,” and together with Recipient Representative and the Company, the “Recipients”).
Supplier and the Recipients collectively are referred to herein as the “Parties.” Capitalized terms used but not defined herein shall have the meaning assigned to such terms in the Purchase Agreement (defined below). 

Recitals 
 WHEREAS,
Supplier, Recipient Representative, the Company and certain other parties entered into a Purchase and Sale Agreement, dated as of March 7, 2015 (the “Purchase Agreement”), pursuant to which, among other things, Supplier and its
Affiliate agreed to sell and transfer, and Recipient Representative and the Company agreed to purchase, the Transferred Interests; 

WHEREAS, the Recipients desire to obtain from Supplier, on the terms and subject to the conditions set forth herein, certain services
following consummation of the transactions contemplated by the Purchase Agreement, and Supplier is willing to provide (or cause to be provided) to the Recipients, on a transitional basis and on the terms and subject to the conditions set forth
herein, such services; and 
 WHEREAS, concurrently with entry into this Agreement, Recipient Representative is entering into an
indemnification agreement with [* * *] in the form attached hereto as Exhibit A. 
 Agreement 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements set forth herein and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows: 

ARTICLE I. 
 SERVICES

 Section 1.1 Purchase and Sale of Services. 

(a) Supplier by itself or through its Affiliates agrees to provide to the Recipients, on the terms and subject to the conditions of this
Agreement and in consideration of the Service Charges described below, the services described in Schedule I, Schedule II, and Section 1.2 (each individually a “Service” and collectively, the
“Services”) for the period designated for each such Service set forth in Section 6.1. 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (b) At any time following the Closing Date, the Parties may agree in writing to add to,
delete or modify the Services set forth on Schedule I or Schedule II. The costs for Services that are added to Schedule I or Schedule II pursuant to this Section 1.1(b) shall be determined in accordance with
Section 2.1. 
 (c) In performing its obligations under this Agreement, Supplier (or its Affiliates, as applicable) shall: 

(i) provide the Services in a commercially reasonable manner that is, to the extent applicable, consistent with the manner in
which they have been provided in the preceding twelve months and in accordance with the policies and procedures of Supplier in place as of the Closing Date; 

(ii) subject to Section 3.1, maintain the necessary resources (human and technological) to provide the Services;

 (iii) use commercially reasonable efforts to obtain the authorizations, memberships, licenses, approvals, consents or
qualifications of any person as may be necessary for the performance of its obligations pursuant to this Agreement, including obtaining from third party providers all consents necessary to grant any sublicenses in connection with the performance of
Services hereunder and maintain such authorizations, memberships, licenses, approvals, consents and qualifications in full force and effect. 

(A) Any fee or extra cost charged to Supplier or its Affiliates by third party providers in connection with any such requested
consents shall be paid directly by the Supplier and invoiced to the Recipient Representative at cost in accordance with Section 2.2. To the extent that a third party provider charges Recipients directly, Recipients may pay such third
party providers directly and shall not be liable to Supplier for such amounts paid to third party providers. 
 (B) In the
event that the consent of a third party provider, if required, is requested by Supplier and is not obtained within thirty (30) days following the Closing Date, Supplier shall notify Recipient Representative and shall cooperate with Recipient
Representative to provide an alternate means of providing the Services affected by such failure to obtain consent, such alternative to be reasonably satisfactory to Recipient Representative. In the event that such an alternative is required,
Supplier shall provide the Services in such alternative manner and Recipient Representative shall bear any expenses incurred in the provision of such Services through such alternative means. 

(d) All Services listed on Schedule I and Schedule II shall be coordinated through a designated service coordinator set forth
opposite such Service. Schedule I and Schedule II shall be updated to reflect any changes to the designated service coordinator by giving notice to the Recipient Representative. 

  
 2 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (e) The Parties acknowledge the transitional nature of the Services. Accordingly, as
promptly as practicable following the execution of this Agreement, Recipients agree to use commercially reasonable efforts to make a transition of each Service to its own internal organization or to obtain alternate third party sources to provide
the Services; provided, that nothing in this Section 1.1(e) shall limit the term of such Services as provided in this Agreement or be interpreted as an agreement to transition such Services prior to the expiration of the term of
such Services set forth herein. 
 (f) The Parties acknowledge that the Services are provided for the purpose of integration only, and not
for any other purpose, including resale of the Services. 
 Section 1.2 Consulting Services. 

(a) From the date hereof until July 15, 2015, [* * *] shall serve as acting General Manager of the facility located at 1300 Gould Drive,
Gainesville, GA 30504 (the “Alkermes Gainesville Facility”) and as an advisor to the management of Recipient Representative. Except for the period from April 20, 2015 through April 25, 2015, during which [* * *] will
attend in-person meetings of Supplier and its Affiliates and be absent from the Alkermes Gainesville Facility, from the date hereof until July 15, 2015, [* * *] shall exclusively provide services to Recipients, and may only provide services to
Supplier with the prior written approval of Recipient Representative (which approval may not be unreasonably delayed, conditioned or withheld). Recipients shall bear no cost for such services provided by [* * *] to Supplier during such period. 

(b) After July 15, 2015, [* * *] shall be reasonably available via telephone or, upon reasonable advance notice to [* * *] and Supplier,
in person at the Alkermes Gainesville Facility to act as an advisor to the management of Recipient Representative until the earlier of: (i) October 1, 2015 or (ii) the Recipient Representative’s notice to Supplier that [* *
*]’s services as an advisor are not required, at which point [* * *] will have no continuing obligation to the Recipients except as set forth in Section 1.2(c). As an advisor to the management of Recipient Representative, [* * *]
shall not have decision-making authority concerning the Alkermes Gainesville Facility and its operations and all decisions concerning the Alkermes Gainesville Facility and its operations shall be made by the management of Recipient Representative or
their other designated individuals. 
 (c) After October 1, 2015 until the conclusion of the 2015 audit, [* * *] shall be reasonably
available, upon reasonable advance notice to [* * *] and Supplier, via telephone to answer questions from the management of Recipient Representative regarding the 2015 audit. 

(d) Nothing in this Agreement will be interpreted as a contract for [* * *]’s employment. All Services provided by [* * *] in accordance
with Sections 1.2(a), 1.2(b) and 1.2(c) shall be performed subject to the terms of [* * *]’s employment with Supplier. For clarity, if [* * *]’s employment with Supplier shall be terminated for any reason, or if [* *
*] shall be unable to perform the services set forth in Sections 1.2(a), 1.2(b) and 1.2(c), Supplier shall have no further obligation under such sections. 

  
 3 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Section 1.3 Third Party Service Providers. It is understood and agreed that
Supplier has been retaining, and will continue to retain, third party service providers to provide some of the Services to the Recipients. In addition, Supplier shall have the right to hire other third party service providers to provide all or part
of any Service, provided that the hiring of such other third party providers does not adversely affect the provision of the Services by Supplier; provided, however, that Supplier shall not hire other third party service providers to provide all or
part of any Service to the extent such hire would materially increase the costs of such Services without the prior written consent of Recipient Representative. In the event that Recipient Representative does not provide such prior written consent,
Supplier shall have the right to immediately terminate the provision of Services proposed to be provided by such third party service provider. Supplier shall in all cases retain responsibility for the provision to the Recipients of Services to be
performed by such third party service provider. Notwithstanding the foregoing, Supplier shall not hire a different third party provider to provide the Services to be provided by Clarkson Consulting without the prior written consent of Recipient
Representative (which consent may not be unreasonably delayed, conditioned or withheld). 
 Section 1.4 Force Majeure. 

(a) Supplier shall notify Recipient Representative of any circumstances beyond the reasonable control of Supplier including, but not limited
to, war, insurrection, riot, civil commotion, acts of terrorism, act of God, market closure (which is not in the ordinary course of business), fire, water damage, explosion, mechanical breakdown, any law, decree, regulation or order of any
government or governmental body (including any court or tribunal), any material interruption in telecommunications, Internet or utilities services that prevents, hinder or delays Supplier from performing its obligations under this Agreement (a
“Force Majeure Event”). 
 (b) In the event that Supplier is prevented, hindered or delayed from performing its
obligations under this Agreement, in whole or in part, due to a Force Majeure Event, then (i) the affected provisions and/or other requirements of this Agreement shall be suspended to the extent necessary during the period of such disability,
and (ii) Supplier shall have no liability to the Recipients or any other party in connection with such suspension. Supplier shall use its commercially reasonable best efforts to resume full performance of this Agreement as soon as reasonably
practicable following the conclusion of the Force Majeure Event. From the commencement and during the continuance of a Force Majeure Event, Recipients may replace, at their sole expense, any affected Service by providing such Service internally or
engaging a third party to provide such Service and Supplier shall reasonably cooperate with such efforts. 
 Section 1.5
Records. Each Party shall keep or cause to be kept full and accurate records (the “Records”) existing or generated as part of the Services performed in connection with this Agreement in accordance with European Union, U.S.,
and International Conference on 

  
 4 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) records retention requirements. Such Records shall be made available to the other Parties promptly
on request in such format as may be reasonably requested at the requesting Party’s cost. 
 Section 1.6 Audit Request.
Recipients will have the right upon thirty (30) days prior written notice to Supplier to audit the records of Supplier or its Affiliates through an independent certified accountant selected by Recipients, and which is reasonably acceptable to
Supplier, for the purposes of confirming (i) that Supplier has complied with its obligations to deliver the Services and (ii) the accuracy of the Service Charges as set forth in Section 2.1, in each case, in accordance with
this Agreement. Supplier shall make its employees reasonably available to Recipients and its accountant in order to provide access to the systems, documentation and records that are the subject of any such audit. Such accountant must have executed
and delivered to Supplier a confidentiality agreement as reasonably requested by Supplier, which will include provisions limiting such accountant’s disclosure to Recipients to only the results of such audit and any information necessary for
Recipients and Supplier to determine whether Supplier has complied with its obligations to deliver the Services. The results of such audit will be referred to (A) for Recipients, Gerri Henwood, Chief Executive Officer and (B) for Supplier,
Blair Jackson, Vice President of Business Development, who shall use commercially reasonably efforts to address and resolve those findings identified by the independent certified accountant as not in compliance with the obligations under this
Agreement. If the matter has not been resolved within thirty (30) days of the matter being referred under the foregoing clause, then the findings of the independent certified accountant, including any destruction order given by the independent
certified accountant, will be binding on both Parties and the Parties shall remedy those items found to not be in accordance with this Agreement. 

Section 1.7 Mutual Confidentiality. 

(a) Except as expressly permitted pursuant to this Agreement, the Purchase Agreement, the Ancillary Agreements, the Intellectual Property
Transfer and License Agreement and the IP License Agreement, the Parties shall refrain from, either alone or in conjunction with any other Person, or directly or indirectly through their Affiliates or Representatives, disclosing to any other Person,
or using in any manner, any confidential, proprietary or secret information (“Confidential Information”) of any other Party or such Party’s Affiliates; provided that the foregoing obligations of confidentiality and non-use will
not apply to any Confidential Information that (A) is or becomes generally available to the public or otherwise part of the public domain and other than through any act or omission of the foregoing Persons or their Affiliates in breach of this
Agreement, the Purchase Agreement, the Ancillary Agreements, the Intellectual Property Transfer and License Agreement or the IP License Agreement, (B) is disclosed after the date hereof to the foregoing Persons or their Affiliates or
Representatives on a non-confidential basis by a third party that is not subject to an obligation of confidentiality with respect to such Confidential Information, and (C) is independently discovered or developed by the foregoing Persons or
their Affiliates without the aid, application, or use of such Confidential Information. 

  
 5 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (b) Notwithstanding Section 1.7(a), a Party may disclose Confidential Information in
order to comply with (i) a request or requirement by deposition, interrogatory, request for documents, subpoena, civil investigation demand or similar process or a formal request from a regulatory examiner, if in the reasonable opinion of
counsel, such disclosure is necessary for such compliance (an “External Demand”); and (ii) only with respect to Confidential Information that is not Restricted Information (as defined below), to its Affiliates; provided
that, (A) with regard to disclosure under clause (i), prior to making such disclosure, the Party subject to such demand or request shall (x) immediately notify the other Party of the existence, terms and circumstances surrounding such
External Demand, (y) consult with the other Party on the availability of taking legally available steps to resist or narrow such request or disclosure, and (z) assist the other Party, at the other Party’s expense, in seeking a
protective order or other appropriate remedy to the extent available under the circumstances and (B) with regard to disclosure under clause (ii), prior to making such disclosure, the recipient of such Confidential Information shall be bound by
obligations of confidentiality with respect to the use and disclosure of such Confidential Information that are at least as stringent as the obligations of confidentiality set forth herein. Recipient shall not, and shall cause its Affiliates and
Representatives not to, access any Restricted Information. For purposes of this Section 1.7, “Restricted Information” shall mean information accessed through Veeva Vault that is not necessary to continue operating the
Alkermes Gainesville Facility under cGMPs. 
 (c) The obligations of confidentiality set forth in this Section 1.7 shall be in
addition to, and shall not amend, modify or otherwise limit, any obligations of confidentiality or non-disclosure as set forth in the Purchase Agreement. 

ARTICLE II. 
 SERVICE
CHARGES 
 Section 2.1 Service Charges. 

(a) As compensation for the Services to be provided hereunder, Recipient Representative shall pay to Supplier or its Affiliate (as designated
by Supplier on a Service-by-Service basis): 
 (i) for Services set forth on Schedule I, the actual out-of-pocket
costs (including the costs of obtaining authorizations, memberships, licenses, applications, approvals, and consents pursuant to Section 1.1(c)(iii)) incurred by Suppliers and its Affiliates to provide such Services; provided,
that Recipient Representative shall not pay the out-of-pocket costs for those Services set forth on Schedule I that Suppliers or its Affiliates would ordinarily use internal resources (e.g., headcount) to address; 

(ii) for Services set forth on Schedule II, Supplier’s and its Affiliates’: (i) standard full time
equivalent rate of $[* * *] per hour plus (ii) actual out of pocket costs (including the costs of obtaining authorizations, memberships, licenses, approvals, applications and consents pursuant to Section 1.1(c)(iii)),
incurred by Supplier and its Affiliates to provide such services; 

  
 6 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (iii) for the Services provided by [* * *] in accordance with
Section 1.2(a), Supplier’s and its Affiliates’ (i) cost of [* * *]’s salary, plus the costs of associated employee benefits, for such three month period plus (ii) actual out-of-pocket costs, incurred by
Supplier and its Affiliates to provide the Services; and 
 (iv) for the Services provided by [* * *] in accordance with
Sections 1.2(b) and 1.2(c), Supplier’s and its Affiliates’: (i) fully burdened monthly rate for [* * *] plus (ii) actual out-of-pocket costs, incurred by Supplier and its Affiliates to provide the
Services as requested by Recipients. 
 The costs and rates referenced in clauses (i) through (iv) above (the “Service
Charges”) shall each be evidenced by Supplier’s or its Affiliates’ records. 
 (b) If at any time the nature of the
Services provided pursuant to this Agreement changes materially in scope from the original proposed allocations set forth in Section 2.1(a), the Service Charges associated with such Service shall be recalculated to a mutually agreeable
rate and agreed to in good faith between Supplier and Recipient Representative. 
 (c) Payments made by Recipient for goods and services
provided by Supplier under this agreement are exclusive of any federal, state, county or municipal sales or use tax, value added tax, excise or similar charge, or other Tax assessment (other than Income Tax), which will be additionally payable by
Recipient in the event that such Tax applies to any of these payments, provided that Supplier will issue an appropriate invoice to support any such charge. If Recipient Representative reasonably believes it is required by law to pay or withhold any
Income Tax on behalf of Supplier with respect to any amounts payable to Supplier under this Agreement, then (i) Recipient Representative shall notify Supplier of its intention to withhold no later than fifteen (15) days before the payment
is due (and such notice shall be sent to the persons designated in Section 7.4(a)); (ii) Recipient Representative shall deduct the Income Taxes from the amount of such monies due; (iii) any such Income Tax required to be paid or
withheld shall be an expense of and borne solely by Supplier; and (iv) Recipient Representative shall promptly provide Supplier with a certificate or other documentary evidence to enable Supplier to support a claim for a refund or a foreign tax
credit. Supplier and Recipient Representative agree to cooperate in all respects to take advantage of any double taxation agreements or similar agreements as may, from time to time, be available in order to enable Recipient Representative to make
such payments to Supplier without any deduction or withholding of Income Tax. Notwithstanding the foregoing, it is understood and agreed that: (1) so long as Supplier has provided Recipient Representative with (A) a properly completed Form
W-8BEN-E establishing its status as the beneficial owner for purposes of the U.S.-Ireland Treaty of the payments of any Service Charges made to Supplier hereunder and its claim to treaty benefits under Article 7 of the U.S.-Ireland Treaty (relating
to Business Profits), and such W-8BEN-E has not expired, Recipient Representative shall treat all such payments to Supplier as exempt from withholding of U.S. federal Income Taxes, and (B) a Form W-8BEN-E upon which Recipients may rely to show
that the payments made to Supplier are not subject to FATCA withholding, Recipients shall not withhold any amounts under FATCA from payments made to Supplier hereunder; and (2) with 

  
 7 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
respect to any payments to an Affiliate of Supplier (as designated pursuant to Section 2.1(a)), so long as such Affiliate has provided Recipient with a properly completed W-9 or other
documentation that establishes to Recipient’s satisfaction that such Affiliate is exempt from backup withholding, Recipient shall treat any payments made hereunder to such Affiliate of Service Charges as exempt from withholding of U.S. federal
Income Taxes and from information reporting under Chapter 61 of the Code. 
 (d) All Service Charges payable under this Agreement shall
become due immediately upon termination (in whole or in part) or expiration of this Agreement. 
 Section 2.2 Invoicing and
Settlement of Costs. 
 (a) During the Term of this Agreement, Supplier shall deliver to the Recipient Representative each month an
invoice in respect of the Services provided to the Recipients and any costs incurred in connection with such Services during the previous month, such invoice to include any pass through costs incurred by Supplier and its Affiliates. Such invoices
shall list the fee for the Services rendered and set forth in reasonable detail the basis for the allocation of such fees to the Recipients. The invoice shall state the amount due in respect of the Services provided during the previous month and
shall be a valid tax invoice for VAT purposes. 
 (b) The Recipient Representative shall pay to Supplier, to such account as may be
specified in writing by Supplier from time to time, all amounts not disputed in good faith and specified in such invoice on or before the forty-fifth (45th ) day following the date of receipt of
the relevant invoice. 
 (i) In the event of a good faith dispute as to the propriety of the amount invoiced, the Recipient Representative
shall pay all undisputed amounts, but shall be entitled to withhold payment of any amount in dispute and shall notify Supplier promptly following receipt of any disputed invoice of the disputed amount and the reasons each such charge is disputed by
the Recipient Representative. 
 (ii) Upon delivery of such notice, Supplier and Recipient Representative shall use reasonable commercial
efforts to resolve any such dispute promptly. 
 (iii) If the matter has not been resolved within thirty (30) days after the delivery
of notice referenced in clause (i) above, then the matter shall be referred to (A) for Supplier, Noeleen Kenny, Vice President Alliance Management and (B) for Recipient Representative, the Chief Financial Officer. The foregoing
representatives of the Parties, or their designees, shall use reasonable commercial efforts to resolve such dispute promptly. 
 (iv) If the
matter has not been resolved within thirty (30) days (or such longer period as may be agreed in writing by the Parties) of being referred under clause (iii) above then the Parties may initiate formal legal proceedings with respect to such
dispute. 

  
 8 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 ARTICLE III. 

PERSONNEL 

Section 3.1 Right to Designate and Change Personnel. Supplier will make available such qualified personnel as will be required to
provide the Services. Nothing in this Agreement shall limit the Supplier’s and its Affiliates’ ability to remove any personnel or terminate any personnel at any time. Notwithstanding anything to the contrary contained in this Agreement,
including, without limitation, the contents of Schedule I and Schedule II, Supplier and its Affiliates shall not be required to retain any of their employees after the Closing that they do not choose to retain in their sole discretion.

 Section 3.2 Access to Premises. Recipients shall allow reasonable access to any premises at which the Services are provided
to suitable personnel of Supplier and its Affiliates or subcontractors as necessary for the provision of Services. Supplier and its Affiliates shall ensure that its personnel allowed access pursuant to the provisions of this Section 3.2
comply with all reasonable safety, confidentiality, and security requirements provided to them from time to time by the Recipients. 

Section 3.3 Not a Contract of Employment. It is acknowledged by the Parties that this Agreement constitutes a contract for the
provision of services and not a contract of employment. Accordingly, during the Term of this Agreement, each Party shall retain overall control of its personnel at all times and be responsible for the payment of all remuneration and benefits of any
kind (including all salaries, holiday pay, tax, health insurance, pay related social insurance payments and contributions to pension arrangements) and shall make all proper deductions from the remuneration that it pays to its employees, personnel
and subcontractors. 
 ARTICLE IV. 

DISCLAIMER OF WARRANTIES 

Section 4.1 Disclaimer of Warranties. Except as expressly provided in this Agreement, the Parties agree that the information
provided hereunder is provided without assertion that it is complete and such information and the Services provided hereunder are provided in both cases with no warranties, and Supplier and its Affiliates expressly disclaim any warranties arising as
a result of this Agreement, whether express, implied or statutory. 
 Section 4.2 Liability of Supplier and its Affiliates.
Supplier and its Affiliates undertake to perform only such duties as are expressly set forth herein and no duties shall be implied. Supplier and its Affiliates shall have no liability under and no duty to inquire as to the provisions of any
agreement other than this Agreement. Supplier’s and its Affiliates’ sole responsibility with respect to this Agreement shall be for the provision of Services in accordance with the terms of this Agreement. If the delivery or provision of
Services shall be stayed or enjoined by any court order, or in case any order, judgment or decree shall be made or entered by any court affecting such services or any part thereof, then and in any such event, Supplier and its

  
 9 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Affiliates are authorized, in their sole discretion, to rely upon and comply with any such order, writ, judgment or decree which they are advised by legal counsel selected by them is binding upon
them without the need for appeal or other action; and if Supplier or its Affiliates comply with any such order, writ, judgment or decree, they shall not be liable to any of the Parties hereto or to any other person or entity by reason of such
compliance even though such order, writ, judgment or decree may be subsequently reversed, modified, annulled, set aside or vacated. 

ARTICLE V. 

INDEMNIFICATION AND LIMITATION OF LIABILITY 

Section 5.1 Indemnification by Supplier. Subject to the provisions of this Article V, Supplier shall indemnify and hold
harmless the Recipients, and each of their respective directors, officers, employees and agents, and each of their heirs, executors, successors and assigns of any of the foregoing from and against any and all Losses actually suffered or incurred by
them arising out of or resulting from Supplier’s or its Affiliates’ (i) breach of this Agreement, (ii) violation of applicable law in performing the Services; (iii) bad faith, gross negligence or willful misconduct in
performing the Services; or (iv) claiming benefits on a form W-8BEN-E pursuant to Section 2.1(c) of this Agreement to which Supplier was not entitled. 

Section 5.2 Indemnification by Recipients. The Recipients shall indemnify and hold harmless: 

(a) Subject to the provisions of this Article V, Supplier and its Affiliates, and each of their respective directors, officers,
employees and agents, and each of their heirs, executors, successors and assigns of any of the foregoing for all Losses actually suffered or incurred by them arising out of or resulting from the Recipients’ (i) breach of this Agreement,
(ii) violation of applicable law in respect of the Services provided hereunder; or (iii) bad faith, gross negligence or willful misconduct in respect of the Services provided hereunder; and 

(b) Subject to the provisions of this Article V, Supplier and its Affiliates and each of their respective directors, officers,
employees and agents, and each of their heirs, executors, successors and assigns of any of the foregoing for all Losses actually suffered or incurred by them arising out of or resulting from the Services provided in accordance with
Section 1.2. 
 Section 5.3 Limitation on Liability. No Party shall be entitled to indemnification pursuant to this
Article V to the extent that such Losses resulted from such Party’s bad faith, gross negligence, willful misconduct or failure to comply with applicable laws. Except with respect to liability arising under Section 5.2(b) or
from a breach of Section 1.7 of this Agreement, such indemnification obligations shall not exceed [* * *] hereunder. Except with respect to liability arising under Section 5.2(b) of this Agreement or a breach of
Section 1.7 of this Agreement, notwithstanding anything to the contrary contained in this Agreement, none of the Parties shall have any liability under any provision of this Agreement for any punitive, incidental, consequential, special
or indirect damages, including loss of future profits, revenue or income, diminution in value or loss of business reputation or opportunity relating to the breach or alleged breach of this Agreement, regardless of whether such damages were
foreseeable. 

  
 10 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Section 5.4 Indemnification Procedures. The procedures set forth in
Section 10.4 of the Purchase Agreement shall be deemed incorporated into, and made part of, this Agreement. 
 Section 5.5
Mitigation. The provisions set forth in Section 10.6 of the Purchase Agreement shall be deemed incorporated into, and made part of, this Agreement. 

Section 5.6 Entire Indemnification; Waiver. The provisions in Sections 5.1 through 5.6 of this Agreement constitute
the complete agreement between the Parties with respect to indemnification under this Agreement, and each Party waives its right to assert any common-law indemnification or contribution claim against the other party with respect to such subject
matter. 
 Section 5.7 Specific Performance. The Parties agree that irreparable damage, for which monetary damages (even if
available) may not be an adequate remedy, might occur in the event that the Parties breach any provision of Section 1.7 of this Agreement. Accordingly, the Parties acknowledge and agree that, to prevent breaches or threatened breaches by the
Parties of any of their respective covenants or obligations set forth in Section 1.7 of this Agreement and to enforce specifically the terms and provisions of Section 1.7 of this Agreement, the Parties shall be entitled to seek an
injunction, specific performance and other equitable relief to prevent breaches of Section 1.7 of this Agreement and to enforce specifically the terms and provisions of Section 1.7 of this Agreement, in addition to any other remedy to
which they are entitled in law or in equity. 
 ARTICLE VI. 

TERM AND TERMINATION 

Section 6.1 Term. The term of this Agreement shall commence on the date hereof and unless earlier terminated pursuant to
Section 6.2, shall continue in full force until the earlier of the expiration of the specified period for each of the Services set forth below or completion of the Services (the “Term”); provided, that the Term
for any Service may be extended or shortened by written agreement of the Parties. 
 (a) The Services set forth on Schedule I shall
terminate sixty (60) days after the Closing Date, provided, however, that the Recipients shall have the right to reasonably request additional information or documentation related to the Services set forth on Schedule I for an additional
number of days as reasonably agreed among the Parties and Supplier shall make a good faith effort to provide such requested information or documentation. 

(b) The Services set forth on Schedule II shall terminate on June 30, 2016. 

(c) The term of the Services provided pursuant to Section 1.2 are set forth in Section 1.2. 

Section 6.2 Termination. Notwithstanding Section 6.1, this Agreement or any of the Services provided for hereunder may
be terminated at any time prior to the expiration of the Term: 
 (a) by mutual written consent of the Parties; 

  
 11 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (b) by the Recipients by giving five (5) Business Days prior written notice to the
Supplier, provided, however, that Services which require cooperation of a third party or parties for cessation shall be terminated as promptly as practicable following such five (5) Business Day notice period; and 

(c) by Supplier by giving thirty (30) days prior written notice to the Recipient Representative of Recipient Representative’s
failure to pay material amounts not in dispute that are greater than ninety (90) days past due. 
 Section 6.3 Effect of
Termination. Other than as required by law, upon termination of any Service pursuant to Section 6.1 or Section 6.2, Supplier will have no further obligation to provide the terminated Service (or any Service, in the case
of the termination of this Agreement) and the Recipients will have no obligation to pay any fees relating to such Service or make any other payments hereunder; provided, however, that notwithstanding such termination, (i) the
Recipients shall remain liable to Supplier for fees owed and payable in respect of Services provided prior to the effective date of the termination and (ii) the provisions of Article II, Article IV,
Article V, Article VI, and Article VII shall survive any such termination. 
 ARTICLE VII. 

MISCELLANEOUS 

Section 7.1 Relationship. The Parties acknowledge and agree that this Agreement does not create a fiduciary relationship,
partnership, joint venture or relationships of trust or agency between the Parties and that all Services are provided by Supplier and its Affiliates as independent contractors. 

Section 7.2 Entire Agreement. This Agreement (including Schedule I and Schedule II) and the Purchase Agreement (and the agreements
and other documents referred to herein and therein) constitute the final agreement between the Parties with respect to the subject matter hereof, and is the complete and exclusive statement of the Parties’ agreement on the matters contained
herein. All prior and contemporaneous negotiations and agreements between the Parties with respect to the matters contained herein are superseded by this Agreement. 

Section 7.3 Cooperation. Each Party will cooperate with the other Parties and provide the other Parties such information with
respect to the performance of any requirement of this Agreement as may be reasonably requested. 
 Section 7.4 Notices. All
notices and other communications to be given to any Party hereunder shall be sufficiently given for all purposes hereunder if in writing and delivered by hand, courier or overnight delivery service or three (3) days after being mailed by
certified or registered mail, return receipt requested, with appropriate postage prepaid, or when received in the form of telegram or facsimile and shall be directed to the address set forth below (or at such other address or facsimile number as
such Party shall designate by like notice): 

  
 12 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	(a)	If to Supplier or its Affiliates: 

 Alkermes Pharma Ireland Limited 

Connaught House 
 1 Burlington
Road 
 Dublin 4, Ireland 

Attn:     Noeleen Kenny, Vice President Alliance Management 

Fax No.: +(353) 1 772 8001 

with a copy (which shall not constitute notice) to: 

Goodwin Procter LLP 
 53 State
Street 
 Boston, MA 02109 

Attn:     Mitchell S. Bloom, Esq. 

             Robert E. Puopolo, Esq. 

Fax No.: (617) 523-1231 

and with a copy (which shall not constitute notice) to: 

Arthur Cox 
 Earlsfort Centre

 Earlsfort Terrace 
 Dublin
2, Ireland 
 Attn:     Christopher P.J. McLaughlin 

Fax No.: +(353) 1 616 3901 
  

	 	(b)	If to Recipient Representative or Recipients, to: 

 Recro Pharma, Inc. 

490 Lapp Road 
 Malvern, PA
19355 
 Attn:     Charles Garner, Chief Financial Officer 

Fax No.: (484) 395-2471 

with a copy (which shall not constitute notice) to: 

Pepper Hamilton LLP 
 Two Logan
Square 
 Eighteenth and Arch Streets 

Philadelphia, PA 19103 

Attn:     Rachael M. Bushey, Esq. 

Fax No.: (800) 860-1682 

  
 13 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Section 7.5 Assignment. This Agreement may not be assigned by any Party, by
operation of law or otherwise, without the express written consent of the other Parties (which consent may not be unreasonably delayed, conditioned or withheld); provided, however, that any Party may assign, mortgage, charge or dispose
of any of its rights or obligations under this Agreement without the prior written consent of the other Parties (i) in the event of a merger, sale or similar transaction involving all or substantially all of its assets, provided that doing so
does not add any obligations to provide Services hereunder or (ii) to an Affiliate. In addition, any Party may designate an Affiliate to perform its obligations hereunder, provided that such Party shall remain fully responsible for the
performance of its respective obligations hereunder. 
 Section 7.6 Governing Law Jurisdiction and Forum; Waiver of Jury Trial.

 (a) This Agreement, and all claims or causes of action (whether based on contract, tort or any other theory) that may be based upon,
arise out of or related to this Agreement or the negotiation, execution or performance of this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware applicable to contracts negotiated, made and performed
in such State without giving effect to the choice of law principles of such State or other jurisdiction that would require or permit the application of the laws of another jurisdiction. 

(b) Each of the Parties hereto irrevocably consents to the exclusive jurisdiction and venue of any court within the State of Delaware in
connection with any matter based upon or arising out of this Agreement or the matters contemplated herein, agrees that process may be served upon them in any manner authorized by the laws of the State of Delaware for such Persons and waives and
covenants not to assert or plead any objection which they might otherwise have to such jurisdiction, venue and such process 
 (c) Each
Party to this Agreement knowingly, intentionally and voluntarily waives to the fullest extent permitted by applicable Law trial by jury in any Action brought by any of them against any other arising out of or in any way connected with this
Agreement, or any other agreements executed in connection herewith or the administration thereof or any of the transactions contemplated herein or therein. No Party to this Agreement shall seek a jury trial in any Action based upon, or arising out
of, this Agreement or any related instruments or the relationship between the Parties. No Party will seek to consolidate any such Action in which a jury trial has been waived with any other Action in which a jury trial cannot be or has not been
waived. Each Party to this Agreement certifies that it has been induced to enter into this Agreement or instrument by, among other things, the mutual waivers and certifications set forth above in this Section 7.6. No Party has in any way
agreed with or represented to any other Party that the provisions of this Section 7.6 will not be fully enforced in all instances. 

Section 7.7 Severability. If any term or other provision of this Agreement is held to be invalid, illegal or incapable of being
enforced by any law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any
manner materially adverse to any party. Upon such determination that any term or other 

  
 14 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
provision is invalid, illegal or incapable of being enforced, the Parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as
closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. 

Section 7.8 Headings. The descriptive headings contained in this Agreement are for convenience of reference only and shall not
affect in any way the meaning or interpretation of this Agreement. 
 Section 7.9 Amendment. The Parties may amend this
Agreement only by a written agreement signed by all Parties that identifies itself as an amendment to this Agreement. 
 Section 7.10
Counterparts. This Agreement may be executed in one or more counterparts, and by the different Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall
constitute one and the same agreement. This Agreement may be executed in delivered by facsimile or other electronic transmission. 
 [
SIGNATURE PAGE FOLLOWS ] 

  
 15 

 IN WITNESS WHEREOF, this Agreement has been signed by or on behalf of each of the parties set
forth below as of the day first above written. 
  

			
	ALKERMES PHARMA IRELAND LIMITED
		
	By:		 /s/

			Name:
			Title:
	
	RECRO PHARMA, INC.
		
	By:		 /s/

			Name:
			Title:
	
	DV TECHNOLOGY LLC
		
	By:		 /s/

			Name:
			Title:
	
	ALKERMES GAINESVILLE LLC
		
	By:		 /s/

			Name:
			Title:

 [Signature Page to Transition Services Agreement] 

 EXHIBIT A 

Indemnification Agreement 

(Attached) 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 INDEMNIFICATION AGREEMENT 

This Indemnification Agreement (“Agreement”) is made as of April 10, 2015 by and between Recro Pharma, Inc., a
Pennsylvania corporation (the “Company”), and [* * *] (“Indemnitee”). 
 RECITALS 

WHEREAS, Alkermes Pharma Ireland Limited, a private limited company incorporated in Ireland (“APIL”), the Company, DV
Technology LLC, a Delaware limited liability company, and Alkermes Gainesville LLC, a Massachusetts limited liability company, have entered into a transition services agreement as of the date hereof (the “Transition Services
Agreement”); 
 WHEREAS, on behalf of APIL, Indemnitee shall provide certain services to the Company as set forth in Sections
1.2(a), 1.2(b), and 1.2(c) of the Transition Services Agreement (the “Services”); and 
 WHEREAS, in
order to induce Indemnitee to provide the Services to the Company, the Company wishes to provide for the indemnification of, and advancement of expenses to, Indemnitee. 

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree
as follows: 
 Section 1. Not a Contract for Employment. 

(a) Nothing in this Agreement will be interpreted as a contract for Indemnitee’s employment. All services provided by Indemnitee to the
Company shall be performed subject to the terms of Indemnitee’s employment with APIL. 
 (b) This Agreement shall continue in full
force and effect after Indemnitee has ceased to provide the Services. 
 Section 2. Definitions. 

As used in this Agreement: 
 (a)
“Change in Control” shall be deemed to have occurred if (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), other than a trustee or other fiduciary
holding securities under an employee benefit plan of the Company or a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company, is or becomes the
“beneficial owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing twenty-five percent (25%) or more of the total voting power represented by the Company’s then
outstanding Voting Securities, other than such persons (of affiliates of such persons) that currently hold in excess of twenty-five percent (25%) of the 

  
 A-1 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
total voting power represented by the Company’s outstanding Voting Shares on the date hereof, or (ii) during any period of two consecutive years, individuals who at the beginning of
such period constitute the Board of Directors of the Company (the “Board”) and any new director whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds
(2/3) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof, or
(iii) the stockholders of the Company approve a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the Voting Securities of the Company outstanding immediately prior
thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities of the surviving entity) at least fifty percent (50%) of the total voting power represented by the Voting Securities of the Company or
such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of (in one
transaction or a series of transactions) all or substantially all the Company’s assets. 
 (b) “Enforcement Expenses”
shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all
other disbursements or expenses of the types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal from such action, including without limitation the premium, security for, and other costs
relating to any cost bond, supersedes bond, or other appeal bond or its equivalent. 
 (c) “Enterprise” shall mean any
domestic or foreign, for-profit or not-for-profit, corporation (other than the Company), partnership, joint venture, trust, employee benefit plan or other legal entity of which Indemnitee is or was serving as a Representative at the request of the
Company. 
 (d) “Expenses” shall include all reasonable and documented attorneys’ fees, retainers, court costs,
transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in
connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding, including without limitation the
premium, security for, and other costs relating to any cost bond, supersedes bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against
Indemnitee. 
 (e) “Independent Counsel” shall mean a law firm, or a partner (or, if applicable, member) of such a law
firm, that is experienced in matters of contract law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company, any Enterprise or Indemnitee in any matter material to any such party (other than with
respect to 

  
 A-2 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for
indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in
representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above. 

(f) The term “Proceeding” shall include any threatened, pending or completed action, suit, arbitration, alternate dispute
resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, regulatory or
investigative nature in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee is or was providing the Services or by reason of any action taken by Indemnitee or of any action taken on his part
while providing the Services or while serving at the request of the Company as a Representative of any Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification,
reimbursement or advancement of expenses can be provided under this Agreement; provided, however, that the term “Proceeding” shall not include any action, suit or arbitration, or part thereof, initiated by Indemnitee to
enforce Indemnitee’s rights under this Agreement as provided for in Section 13(e) of this Agreement. 
 (g)
“Representative” shall mean a person occupying the position or discharging the functions of a director, officer, employee, fiduciary, trustee or agent thereof, regardless of the name or title by which the person may be designated.
The term does not imply that a director, as such, is an agent of a corporation. 
 (h) “Services” shall have the meaning
set forth in the recitals. 
 (i) “Voting Securities” shall mean any securities of the Company which vote generally in the
election of directors. 
 Section 3. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee in accordance
with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to
this Section 3, Indemnitee shall be indemnified against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or
matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding, had no reasonable cause to believe that his conduct was
unlawful; provided, however, that the Company has no obligation to indemnify the Indemnitee for amounts paid in settlement without the Company’s prior written consent. 

  
 A-3 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Section 4. Indemnity in Proceedings by or in the Right of the Company. The
Company shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment
in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if
Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or
matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the court of common pleas of the judicial district embracing the county in which the registered office of the
Company is located or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to
indemnification for such expenses as the court of common pleas or other court deems proper. 
 Section 5. Indemnification for
Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement and except as provided in Section 8, to the extent that Indemnitee is a party to or a participant in and is successful, on
the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly
successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably
incurred by Indemnitee or on his behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by
dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. 
 Section 6.
Indemnification For Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of providing the Services, a witness in any Proceeding to which Indemnitee is not a party and is not
threatened to be made a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. 

Section 7. Intentionally Omitted. 

Section 8. Exclusions. Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under
this Agreement: 
 (a) to make any indemnity for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder)
if and to the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise; 

  
 A-4 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (b) to make any indemnity or advancement that is prohibited by applicable law; 

(c) to make any indemnity or advancement in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including
any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees. 

Section 9. Advances of Expenses. The Company shall advance, to the extent not prohibited by law, the Expenses incurred by
Indemnitee in connection with any Proceeding, and such advancement shall be made within twenty (20) days after the receipt by the Company of a statement or statements requesting such advances (which shall include invoices received by Indemnitee
in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law shall not
be included with the invoice) from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay the expenses
and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement which shall
constitute an undertaking providing that Indemnitee undertakes to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not
entitled to be indemnified by the Company. The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding, including any appeal therein. Nothing in this Section 9 shall limit
Indemnitee’s right to advancement pursuant to Section 13(e) of this Agreement. 
 Section 10. Procedure for
Notification and Defense of Claim. 
 (a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a
written request therefor and, if Indemnitee so chooses pursuant to Section 11 of this Agreement, such written request shall also include a request for Indemnitee to have the right to indemnification determined by Independent Counsel.

 (b) The Company will be entitled to participate in the Proceeding at its own expense. 

Section 11. Procedure Upon Application for Indemnification. 

(a) Upon written request by Indemnitee for indemnification pursuant to Section 10(a), a determination with respect to
Indemnitee’s entitlement thereto shall be made in the specific case: (i) by Independent Counsel in a written opinion to the Board if Indemnitee so requests in such written request for indemnification pursuant to Section 10(a),
or (ii) by the Company if Indemnitee does not so request such determination be made by Independent Counsel. In the case that such determination is made by Independent Counsel, a copy of 

  
 A-5 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
Independent Counsel’s written opinion shall be delivered to Indemnitee and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within
ten (10) days after such determination. Indemnitee shall cooperate with the Independent Counsel or the Company, as applicable, making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to
such counsel or the Company, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such
determination. Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination as to
Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. 

(b) In the event that Indemnitee exercises his right to have his entitlement to indemnification determined by Independent Counsel pursuant to
clause (i) of Section 11(a), the Independent Counsel shall be selected by Indemnitee. The Company may, within ten (10) days after written notice of such selection, deliver to Indemnitee a written objection to such
selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in
Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written
objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within twenty
(20) days after the later of (i) submission by Indemnitee of a written request for indemnification and Independent Counsel pursuant to Sections 10(a) and 11(a)(i) hereof, respectively, and (ii) the final disposition of
the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been made by the Company to
the selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate. The person with respect to whom all objections are so resolved or the
person so appointed shall act as Independent Counsel under Section 11(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 13(a) of this Agreement, Independent Counsel shall be
discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). 

Section 12. Presumptions and Effect of Certain Proceedings. 

(a) In making a determination with respect to entitlement to indemnification hereunder, it shall be presumed that Indemnitee is entitled to
indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 10(a) of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection
with the making of any determination contrary to that presumption. Neither (i) the failure of the Company or of Independent Counsel to have made a determination 

  
 A-6 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor
(ii) an actual determination by the Company or by Independent Counsel that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard
of conduct. 
 (b) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction,
or upon a plea of guilty, nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not
act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.

 (c) The knowledge and/or actions, or failure to act, of any Representative of the Company or any Enterprise shall not be imputed to
Indemnitee for purposes of determining the right to indemnification under this Agreement. 
 Section 13. Remedies of Indemnitee.

 (a) Subject to Section 13(f), in the event that (i) a determination is made pursuant to Section 11 of this
Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 9 of this Agreement, (iii) no determination of entitlement to
indemnification shall have been made pursuant to Section 11(a) of this Agreement within sixty (60) days after receipt by the Company of the request for indemnification that does not include a request for Independent Counsel,
(iv) payment of indemnification is not made pursuant to Section 5 or 6 or the last sentence of Section 11(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor
or (v) payment of indemnification pursuant to Section 3 or 4 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be
entitled to an adjudication by a court of his entitlement to such indemnification or advancement. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial
Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within one hundred and eighty (180) days following the date on which Indemnitee first has
the right to commence such proceeding pursuant to this Section 13(a); provided, however, that the foregoing time limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under
Section 5 of this Agreement. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration. 

(b) In the event that a determination shall have been made pursuant to Section 11(a) of this Agreement that Indemnitee is not
entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 13 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by

  
 A-7 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 13, the Company shall have the burden of proving Indemnitee is not
entitled to indemnification or advancement, as the case may be. 
 (c) If a determination shall have been made pursuant to
Section 11(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 13, absent
(i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of
such indemnification under applicable law. 
 (d) The Company shall be precluded from asserting in any judicial proceeding or arbitration
commenced pursuant to this Section 13 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the
provisions of this Agreement. 
 (e) The Company shall indemnify Indemnitee against any and all Enforcement Expenses and, if requested by
Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Enforcement Expenses to Indemnitee, which are incurred by Indemnitee in connection with any
action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any liability insurance policies maintained by the Company for coverage of its Representatives, regardless of whether Indemnitee
ultimately is determined to be entitled to such indemnification, advancement or insurance recovery, as the case may be, in the suit for which indemnification or advancement is being sought. 

(f) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement
shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein. 
 Section 14.
Non-exclusivity; Survival of Rights; Insurance; Subrogation. 
 (a) No amendment, alteration or repeal of this Agreement or of any
provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in the course of providing the Services prior to such amendment, alteration or repeal. No right or
remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity
or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 

(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for Representatives of the Company
or of any other Enterprise, Indemnitee shall be covered by any such policy or policies that applies to a Representative of the same position as Indemnitee in accordance with its or their terms to the maximum extent of the

  
 A-8 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
coverage available for any such Representative under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has liability
insurance in effect covering its Representatives, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take
all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. 

(c) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of
recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. 

(d) The Company’s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of
the Company as a Representative of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other Enterprise. 

Section 15. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) three
(3) years after the date that Indemnitee shall have ceased to provide the Services or (b) one (1) year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights
of indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section 13 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and
shall inure to the benefit of Indemnitee and his heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation division or otherwise) to all, substantially all
or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the
Company would be required to perform if no such succession had taken place. 
 Section 16. Severability. If any provision or
provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each
portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain
enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and
(c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself
invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. 

  
 A-9 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Section 17. Enforcement. 

(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in
order to induce Indemnitee to provide the Services, and the Company acknowledges that Indemnitee is relying upon this Agreement in providing such services to the Company. 

(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof. 

Section 18. Modification and Waiver. No supplement, modification or amendment, or waiver of any provision, of this Agreement shall
be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing
waiver. 
 Section 19. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with
any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement as provided hereunder. The failure of Indemnitee to so notify the
Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise, except to the extent that the Company is materially prejudiced by such failure. 

Section 20. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be
deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (ii) mailed by certified or registered mail with postage prepaid, on the third
business day after the date on which it is so mailed, (iii) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (iv) sent by facsimile transmission,
with receipt of oral confirmation that such transmission has been received: 
 (a) If to Indemnitee, at such address as Indemnitee shall
provide to the Company. 
 (b) If to the Company to: 

Recro Pharma, Inc. 
 490 Lapp
Road 
 Malvern, PA 19355 

Attention: Gerri Henwood 
 or to any other
address as may have been furnished to Indemnitee by the Company. 

  
 A-10 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Section 21. Contribution. To the fullest extent permissible under applicable law,
if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines,
penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order to reflect (i) the
relative benefits received by the Company and Indemnitee in connection with the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii) the relative fault of the Company (and its Representatives) and Indemnitee in connection
with such event(s) and/or transactions. 
 Section 22. Applicable Law and Consent to Jurisdiction. This Agreement and the legal
relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant
to Section 13(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in a court of
competent jurisdiction in the State of Delaware (a “Delaware Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive
jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) consent to service of process at the address set forth in Section 20 of this Agreement with the
same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to
plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. 

Section 23. Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed
to constitute part of this Agreement or to affect the construction thereof. 
 Section 24. Identical Counterparts. This
Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom
enforceability is sought needs to be produced to evidence the existence of this Agreement. 
 [Remainder of Page Intentionally Left Blank]

  
 A-11 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and
year first above written. 
  

			
	RECRO PHARMA, INC.
		
	By:		  

			Name:
			Title:
	
	INDEMNITEE
	
	  

	[* * *]

  

	
	Current Indemnitee Address
	
	  

	
	  

	
	  

  
 A-12 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 SCHEDULE I 

Supplier and its Affiliates or subcontractors will provide the following Services subject to the terms of this Agreement and the Purchase Agreement. 

 

							
	 #
	  	 Detailed Description of Service
	  	 Supplier Service
Coordinator
	  	 Recipient Service
Coordinator

				
	1.	  	Transfer of emails and other electronic data (including electronic documents and employee data) related primarily to the Business to the extent not fully transferred to Recipients at Closing.	  	Rutter, Inc. and [* * *]	  	[* * *]
				
	2.	  	Transfer of any hard copy records related primarily to the Business to the extent not fully transferred to Recipients at Closing.	  	[* * *]	  	[* * *]
				
	3.	  	Transfer of the existing safety database for Verelan/Verapamil (Argus database) to Recipients or their nominated third party provider, to the extent not fully transferred to Recipients at Closing, and support Recipient’s
pharmacovigilance and adverse event reporting obligations with respect to Verelan/Verapamil, until June 30, 2015 at the latest. The Parties shall develop a plan by May 15, 2015 for the transport on or before May 28, 2015. Such plan shall be mutually
agreed upon by the parties.	  	[* * *]	  	[* * *]
				
	4.	  	Transfer of ownership for any applications/INDs currently owned by Supplier or its Subsidiaries (other than the Company or Alkermes Gainesville) (e.g. DMF, IND, NDA’s, etc.) that relate solely to the Products to the extent not
fully transferred to Recipients at Closing, provided that Supplier and Recipient shall collaborate with respect to the letters/correspondence to be provided to Governmental Entities regarding transfer of regulatory responsibilities before such
applications/INDs are transferred.	  	[* * *]	  	[* * *]

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

							
	 #
	  	 Detailed Description of Service
	  	 Supplier Service
Coordinator
	  	 Recipient Service
Coordinator

				
	5.	  	Transfer of information with respect to the Business and in the possession and control of Supplier or its Subsidiaries (other than the Company or Alkermes Gainesville) relating to IP/patent litigation and employee litigation,
provided that Supplier shall provide any necessary consents or letters reasonably requested by the Recipient Representative’s legal counsel to transfer such information relating to such litigation, to the extent not fully transferred to
Recipients at Closing.	  	[* * *]	  	[* * *]
				
	6.	  	Transfer of information with respect to the Business and in the possession and control of Supplier or its Subsidiaries (other than the Company or Alkermes Gainesville) relating to R&D related primarily to the Products,
manufacturing and facilities, to the extent not fully transferred to Recipients at Closing.	  	[* * *]	  	[* * *]
				
	7.	  	Transfer of information with respect to the Business and in the possession and control of Supplier or its Subsidiaries (other than the Company or Alkermes Gainesville) relating to Clinical Trial Masterfiles and case report forms and
nonclinical data relating to the Products, to the extent not fully transferred to Recipients at Closing.	  	[* * *]	  	[* * *]
				
	8.	  	Assistance with the support and transfer to Recipients of (i) business relationships, (ii) audit, tax, accounting, financial, insurance, claims handling and treasury functions, (iii) employee files, benefits and recruiting
transition support and (iv) ongoing regulatory activities (CMC, documentation, facilities), in each case of (i) through (iv) primarily related to the Business, to the extent not fully transferred to Recipients at Closing, provided that Supplier will
collaborate with Recipient to transfer such items as soon as reasonably practicable after Closing.	  	[* * *]	  	[* * *]
				
	9.	  	Assistance to Alkermes Gainesville employees who hold stock or stock options in Alkermes plc from Supplier and its Subsidiaries’ captive broker in exercising options, determining tax basis of equity grants, retrieving
tax/transaction reports, and transferring shares to their personal accounts.	  	[* * *]	  	N/A

  
 A-14 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

							
	 #
	  	 Detailed Description of Service
	  	 Supplier Service
Coordinator
	  	 Recipient Service
Coordinator

				
	10.	  	Transfer of flat files, data, and/or an alternate solution (where appropriate) from the items listed on Part I(b) of Schedule II.	  	[* * *]	  	[* * *]
				
	11.	  	Promptly following the Closing, file documentation with relevant patent authorities to effect recordal of transfer of patents, patent applications and trademark registrations in the name of DV Technology LLC from the current owner
of record; provided, that if the Closing occurs before 10:00 a.m., prevailing Eastern time, on the Closing Date, such documentation shall be filed with the United States Patent and Trademark Office on the Closing Date.	  	[* * *]	  	[* * *]
				
	12.	  	Services with respect to SOX controls for Alkermes Gainesville (i.e., documentation that identifies key processes and key controls within those processes).	  	[* * *]	  	[* * *]
				
	13.	  	[* * *]	  	[* * *]	  	[* * *]

  
 A-15 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 SCHEDULE II 

Transition Services 

Part I(a): IT Services 
 Supplier and its
Affiliates or subcontractors will provide the following Services subject to the terms of this Agreement and the Purchase Agreement. 
  

							
	 #
	  	 Detailed Description of Service
	  	 Supplier Service
Coordinator
	  	 Recipient Service
Coordinator

				
	1.	  	SAP Services (including maintenance; GL account creation, cost center creation, reporting hierarchies)	  	[* * *]	  	[* * *]
				
	2.	  	Maximo (Plant Maintenance)	  	[* * *]	  	[* * *]
				
	3.	  	ComplianceWire Learning Management System	  	[* * *]	  	[* * *]
				
	4.	  	LIMS (Thermo Scientific Laboratory Information Management System)	  	[* * *]	  	[* * *]
				
	5.	  	SDMS/ELN (Waters)	  	[* * *]	  	[* * *]
				
	6.	  	SLIM (H&A Scientific Stability Laboratory Information System)	  	[* * *]	  	[* * *]
				
	7.	  	Veeva Vault (QA Doc Mgt) - As a result of the Closing of the Purchase Agreement, Supplier has agreed to provide Alkermes Gainesville with direct access, through Supplier’s controlled document system (Veeva Vault), to those
documents required to continue operating the Alkermes Gainesville Facility (located at 1300 Gould Drive, Gainesville, GA 30504) under cGMPs. Such access will be in effect until Recipients have completed setup of their own self-sustained controlled
document system. Affiliates of Alkermes Gainesville will not have access to Supplier’s Veeva Vault.	  	[* * *]	  	[* * *]

  
 A-16 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

							
	 #
	  	 Detailed Description of Service
	  	 Supplier Service
Coordinator
	  	 Recipient Service
Coordinator

				
	8.	  	Octagon and SafeBio Pharma (Regulatory Submissions and eSignature)	  	[* * *]	  	[* * *]
				
	9.	  	External Collaboration (SharePoint, Extranets)	  	[* * *]	  	[* * *]
				
	10.	  	Intranet Support Services	  	[* * *]	  	[* * *]
				
	11.	  	E-mail (SmartPhone, Tablet, Exchange, External gateways, Mobile Device Management, Spam Filtering, PGP)	  	[* * *]	  	[* * *]
				
	12.	  	IT Help Desk Application (ServiceNow)	  	[* * *]	  	[* * *]
				
	13.	  	Data separation / parsing for each application above	  	[* * *]	  	[* * *]
				
	14.	  	Modifications to existing system configuration, reports and interfaces to support application and source data changes	  	[* * *]	  	[* * *]
				
	15.	  	Development of new reports and interfaces necessary to support Alkermes Gainesville	  	[* * *]	  	[* * *]
				
	16.	  	End-user Computing Infrastructure (Internet, SEP/PGP Wireless, Remote PC Desktop Control, Self-Service P/W Management, PC Helps/Vitalyst desktop support)	  	[* * *]	  	[* * *]
				
	17.	  	Wide Area Network	  	[* * *]	  	[* * *]
				
	18.	  	Active Directory Domain Services Support	  	[* * *]	  	[* * *]
				
	19.	  	Network Infrastructure Services and Support (Backup/Replication, Monitoring, Anti-virus, VMware, Web Filtering, Firewalls, etc.)	  	[* * *]	  	[* * *]
				
	20.	  	Remote Access System Support / VPN	  	[* * *]	  	[* * *]

  
 A-17 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

							
	 #
	  	 Detailed Description of Service
	  	 Supplier Service
Coordinator
	  	 Recipient Service
Coordinator

				
	21.	  	IT Contracts Management and Support	  	[* * *]	  	[* * *]
				
	22.	  	IT Security Services and Support	  	[* * *]	  	[* * *]
				
	23.	  	NextDocs (Change Control)	  	[* * *]	  	[* * *]

 Part I(b): Excluded IT Services 

Supplier and Recipient Representative have agreement that the items listed below on this Part I(b) of Schedule II shall not be transferred to
the Recipients and shall not be included in the definition of “Services.” 
  

	 	•	 	Oracle eBusiness Suite HRIS Services 

  

	 	•	 	Oracle Fusion (Employee Performance and Comp Planning) 

  

	 	•	 	Concur Travel & Expense System 

  

	 	•	 	ADP Payroll/ADP ConnectTaleo (HR Recruiting and Applicant Tracking) 

  

	 	•	 	Okta (Single-Signon) 

  

	 	•	 	Third-Party Personnel Benefit Providers 

  

	 	•	 	Backup Support Services (NetBackup, Data Domain) 

  

	 	•	 	IT Quality Management Services and Support 

  

	 	•	 	IT Management System (ITMS) Framework, Audit and Control Testing Support 

  
 A-18 

 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.
REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Part II: Other 

Supplier and its Affiliates or subcontractors will provide the following Services subject to the terms of this Agreement and the Purchase Agreement 

 

							
	 #
	  	 Detailed Description of Service
	  	 Supplier Service
Coordinator
	  	 Recipient Service
Coordinator

				
	1.	  	Support with respect to ongoing prosecution of the patent applications owned by the Company	  	[* * *]	  	[* * *]

  
 A-19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]